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Resumo 
 
 
 
Recentemente, a utilização de anticorpos para imunoterapia passiva 
tornou-se uma área de investigação atrativa. Tal facto deve-se à 
diminuição da eficiência dos antibióticos pelo aumento do número de 
organismos resistentes. Os anticorpos obtidos a partir da gema do ovo de 
galinhas imunizadas, imunoglobulinas Y (IgY), são uma alternativa viável 
e promissora aos anticorpos de mamíferos. Estes apresentam inúmeras 
vantagens, dado que podem ser obtidos em maior quantidade e serem 
recolhidos por técnicas menos invasivas. Apesar das vantagens 
apresentadas, as técnicas disponíveis para a extração e purificação de IgY 
são demoradas, trabalhosas, apresentam baixo rendimento, levam a baixos 
fatores de pureza, apresentam custos elevados e não são facilmente 
aplicáveis a nível industrial. Assim, o principal objetivo deste trabalho 
consistiu no desenvolvimento de uma plataforma de purificação 
alternativa para a extração e purificação de IgY, utilizando sistemas 
aquosos bifásicos (SAB) constituídos por líquidos iónicos com capacidade 
tampão. Neste trabalho foram estudados SAB constituídos por C6H5K3O7 
e líquidos iónicos, sendo os últimos sintetizados pela combinação de 
aniões com capacidade tampão (Good’s buffers), com os catiões 
tetrabutilamónio ([N4444]
+) e tetrabutilfosfónio ([P4444]
+). Os líquidos 
iónicos utilizados permitiram o estudo da influência do anião e do catião 
nos diagramas de fase, ou seja sob a capacidade dos diferentes líquidos 
iónicos para formar SAB. De seguida, foi testada a capacidade destes 
sistemas como uma plataforma alternativa para a extração seletiva, e 
posterior purificação, de IgY. A purificação de IgY não foi conseguida 
num único passo de extração com os sistemas estudados. No entanto, o 
estudo do perfil proteico de ambas as fases dos sistemas permitiu concluir 
que, durante a partição, todas as proteínas migraram para a fase superior e 
que houve formação de um complexo entre o IL e algumas das proteínas 
constituintes da fração aquosa proteica da gema do ovo. Os resultados 
obtidos revelaram que, entre os vários SAB estudados, o mais promissor 
para a extração de IgY, é aquele constituído por 20.1 (m/m) % 
[N4444][CHES] + 16.9 (m/m) % C6H5K3O7.  
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Abstract 
 
 
 
The increased inefficiency of antibiotics observed in the past few years, 
derived from the growing number of drug-resistant organisms and the 
appearance of individuals with impaired immune system, led to a 
significant research on antibodies for use in passive immunotherapy. 
Antibodies obtained from the egg yolk of immunized hens, 
immunoglobulin Y (IgY), are a promising alternative to mammalian 
antibodies. They can be obtained in higher titres and by less invasive 
techniques, thus opening the door for a new kind of more economic 
biopharmaceuticals. However, the available techniques for the IgY 
extraction and purification are time-consuming, labor intensive, low 
yielding, provide low-purification levels, are of high cost and cannot 
easily be scaled-up for industrial applications. In this work, ABS 
composed of C6H5K3O7 and ILs synthetized by the combination of anions 
with buffer capacity (Good’s buffers), with the tetrabutylphosphonium 
([P4444]
+) and tetrabutylammonium ([N4444]
+) cations, were investigated. 
The use of different ILs allowed the study of the cation and anion nature 
on the phase diagrams behaviour and thus on their ability to form ABS. 
Further, the ability of these systems as an alternative purification platform 
for IgY, by a selective extraction, was studied. The complete extraction 
and purification of IgY was not achieved in a single with the investigated 
ABS. However, the study of the proteins profile of the coexisting phases 
allowed to conclude that all proteins migrate for the top phase during the 
partitioning process, and that a complex between the ILs and the different 
proteins present in the water-soluble fraction of proteins from egg yolk 
was formed. Still, the results obtained reveal that the system composed of 
20.1 wt % [N4444][CHES] + 16.9 wt % C6H5K3O7 is the most promising 
ABS for the IgY extraction. 
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1.1 - Scopes and objectives 
Biopharmaceuticals, such as recombinant therapeutic proteins, antibodies and nucleic 
acids, have greatly improved the treatment and diagnosis of some diseases, being already 
applied in the treatment of anaemia, multiple sclerosis, breast cancer, rheumatoid arthritis 
and diabetes (1–3). The widespread antimicrobial resistance, the emergence of new 
pathogens that cannot be treated with the existing antimicrobial drugs, for instance the 
human immunodeficiency virus (HIV) and Cryptosporidium parvum, and the occurrence 
of many infections in patients with an impaired immune system, in whom antimicrobial 
drugs are less effective, have made of the implementation of antibiotics and antiviral 
therapies a challenge (4–6).  
Therapeutic proteins have revolutionized the treatment of many diseases and more 
than 100 genes, and a similar number of modified proteins, are already approved for 
clinical use in the European Union and in the USA (7). The initial therapeutic proteins 
approved were recombinant insulins and blood factors (8). Recently, protein engineering 
has allowed the development and application of new biopharmaceuticals, such as 
modified insulins, among others (8). Protein engineering entails the controlled alteration 
of a gene’s nucleotide sequence, such that specific pre-determined alterations in the 
resultant polypeptide’s amino acid sequence are introduced (3,8). 
Antibodies are the key proteins of organism’s specific responses to foreign substances 
and they are produced when an antigen receptor binds specifically to a B-cell, triggering 
a mechanism which involves activation, cell division and differentiation (9–12). Because 
of their versatility, antibody-based therapies can be developed against any existing 
pathogen, and with high specificity (4). Antibody-based (serum) therapies were first used 
in the treatment of human infections in the 1890s (5). At that time, antibodies were used 
to treat a variety of bacterial infections, namely those caused by Corynebacterium 
diphtheria, Streptococcus pneumoniae, Neisseria meningitides, Haemophilus influenzae, 
group A streptococcus, and Clostridium tetani (5,6). However, this methodology was 
rapidly left due to its immediate side effects, which include fevers, chills and allergic 
reactions (4,5). Currently, the available techniques for diagnosis and therapy mainly use 
mammalian monoclonal or polyclonal antibodies (13,14). These practices have however 
some disadvantages, such as the weakness of the immunogenic response to monoclonal 
antibodies and the difficulties regarding the production and purification of antibodies 
from mammalian blood, which is low yielding and laborious (13). Some of these 
4 
 
 
disadvantages can be overcame by the use of chicken egg antibodies (IgY) instead of the 
corresponding mammalian immunoglobulins (IgG) (13,14). Nevertheless, the widespread 
use of IgY is still restricted due to problems associated with these antibodies isolation and 
purification from the complex egg yolk matrix (15). Moreover, since the demand for 
biopharmaceuticals is expected to increase in the near future it would be wise to ensure 
that they will be available on a cost-effective basis (16). Therefore, to ensure the IgY 
application at a large scale, as alternative antibodies for use in passive immunotherapy, 
the existing methods should be optimised and/or new techniques should be developed 
(15).  
Aqueous biphasic systems (ABS) offer many advantages, being currently used for 
proteins extraction and for the downstream processing of biopharmaceuticals and some 
of them at a large scale (2). The fact that ABS are mostly composed of water makes of 
them a biocompatible media for biologically active products (17–20). The extraction and 
purification of biological products using ABS has been reported using combinations of 
two hydrophilic solutes (two polymers or a polymer and a salt) dissolved in aqueous 
media (16,21–24). These conventional systems have, however, a restricted polarity 
difference between the two phases, which have been limiting their success in the selective 
extraction and purification of IgY (19). Only one work was found for the purification of 
IgY using micelle-based ABS composed of a phosphate-based salt and Triton X-100 (20). 
Ionic liquids (ILs) are salts that are liquid at low temperatures, and in general they 
remain in the liquid state below the boiling point of water (100 ºC), in contrast to common 
salts (19,25). ILs have been recently used for chemical syntheses, biocatalytic 
transformations and analytical separation processes due to their “greener” characteristics, 
such as a negligible volatility and non-flammability (26). Therefore, they have been 
considered as potential substitutes of volatile and hazardous organic solvents presently 
used in a wide range of applications (19). Rogers and his research team (26) reported, in 
2003, the revolutionary research work on the development of IL-based ABS, by the 
addition of inorganic salts to aqueous solutions of ILs. The main advantage of using ILs 
for ABS formation conveys on the ability to design the cation/anion chemical structures 
and their combinations, allowing thus the tailoring of the polarities and the affinities of 
the coexisting phases in ABS (19). Due to their tunable physicochemical properties, ILs 
can cover the whole hydrophilicity–hydrophobicity range and improved and selective 
extraction can be envisaged (19,25).  
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Based on the main drawbacks associated with the purification of IgY, and main 
advantages of ILs as phase-forming components of ABS, the main purpose of this work 
consists on the development of an alternative platform for the selective extraction and 
purification of IgY, from egg yolk, using ILs derived from biological buffers (zwitterionic 
amino acid derivatives). These ILs, which allow the pH adjustment, were evaluated with 
the objective of preserving the native protein structure and specific activity (25,27). In 
particular, ILs with anions derived from Good’s buffers (GB-ILs) were synthesized and 
characterized (28). The GB-ILs were then used in the formation of ABS and evaluated 
for the extraction and purification IgY from the water soluble fraction of proteins egg 
yolk. 
 
1.2 - Antibodies  
Antibodies are glycoproteins, members of the immunoglobulins family, and they 
encompass one of the principal effects of the immune system (9,10). In the adaptive 
immune response, soluble proteins and cell-surface receptors bind the pathogen and its 
products (serum proteins or human cells that became altered in the presence of the 
pathogen) (29,30). The ability of the immune system to recognize antigens depends on 
the antibodies generated by B-cells and on the antigen receptors expressed by T-cells; 
yet, the way in each one of this type of cells recognizes the pathogen is quite different 
(12). The first sign is delivered by the antigen binding and usually involves a co-receptor, 
in addition to the antigen-receptor on the B-lymphocyte membrane (30). A B-cell binds 
to the antigen receptor, comprising the signal 1. The B-cell engulfs the antigen, processes 
it into peptides in an endosomal compartment, where major histocompatibility complexes 
(MHC) of Class I, II or III are formed (30). MHC is the genetic loci involved in the 
rejection of foreign or non-self-tissues, and in humans it is known as the human leucocyte 
antigen (HLA). The three classes differ considerably in their gene composition, 
presenting different structural identities (12).  Later, the B-cells involve an activated T-
helper cell (TH) specific for the MHC complex (30). T-cell receptors only recognize 
antigens in association with MHC molecules, on the cell surfaces and, as described, these 
antigens have often been degraded or processed into fragments, which are recognized by 
the T-cell receptor (12). The activated TH cells provide a second set of signals to the B-
cells including contact signals or signals delivered by cytokine molecules secreted by the 
T-cell, which include IL-1, IL-2, IL-4, IL-5, IL-6, IL-10 and IFNɤ (30). In the presence 
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of IL-4 and IL-1 the receptors for IL-2 and other cytokines are expressed. Consequently, 
IL-2, IL-4 and IL-5 are secreted by T-cells driving to B-cells activation, proliferation and 
differentiation (Figure 1) (12). An activated B-cell will proliferate and differentiate 
producing antibody secreting plasma cells or memory B cells (30). Memory B cells are 
crucial for the secondary immune response. They are capable to produce a faster and more 
robust antibody-mediated immune response in the case of re-infection (9,30). 
 
Figure 1 – Stages in B-cell activation and development. Ab – Antibody; Ag – Antigen; AFC – Antibody-
forming cells (12). 
 
It is also important to refer that there are a small number of antigens that are capable 
of activating the B-cells without the T-cell help, referred as T-independent antigens 
(12,29,30). These have some particular properties since they are large polymeric 
molecules, they possess the ability, at high concentrations, to activate B-cell clones that 
are specific for other antigens, and many T-independent B-cells are particularly resistant 
to degradation (12). However, the mechanism by which T-independent antigens activate 
the B-cells, without T-cells help, is not fully understood (12). 
Antibodies circulate as major components of the plasma in blood and lymph 
constituting about 20 % of the plasma protein fraction in humans (10,29). The diversity 
and specificity of the antibody-antigen interaction and the ability to manipulate the 
characteristics of this interaction, using recombinant technology, has created many uses 
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for antibodies and antibody fragments in applications such as medicine, passive 
immunotherapy or diagnosis, biomedical research, experimental biology, among others 
(9–11). Both monoclonal and polyclonal antibodies can be used for these purposes 
(11,16). Monoclonal and polyclonal antibodies have many differences regarding their 
nature and which limit or define their use. Polyclonal antibodies are most frequently 
produced and they recognize independent antibody binding sites on the antigen (10,31). 
Hyper-immunised serum is a very good source of polyclonal antibodies, since it contains 
a mixture of antibodies against multiple epitopes (10). Their production starts with the 
immunization of the animal with the specific antigen and, throughout this process, the 
immune response is controlled by the collection of serum titres (32). The desired antigen 
is generally applied in combination with various adjuvant compounds (33). The serum 
containing a polyclonal mixture of specific and non-specific antibodies is collected and 
subjected to purification using techniques such as precipitation and chromatography, 
followed by digestion with proteases, which minimize the antigenicity against the 
species-specific Fc region (32). Polyclonal antibodies are also commonly used in 
immunochemical techniques (10). Moreover, they are also considered more efficient in 
the treatment of acute illness and medical emergencies, as they can bind and neutralize 
multiple epitopes on the disease-causing agent (32). On the other hand, monoclonal 
antibodies are produced by a single B-lymphocyte clone; therefore, all of them are 
identical (31). Monoclonal antibodies can be produced by specialized cells through 
hybridoma technology. A hybridoma is produced by the injection of a specific antigen 
into a mouse, followed by the recovery of the antigen-specific B-cells from the mouse’s 
spleen and the subsequent fusion of this cell with a cancerous immune cell called 
myeloma cell (myeloma is a cancer B-cell) (34). The fused hybrid cell, hybridoma, can 
be cloned producing therefore many identical daughter clones and large amounts of the 
desired antibodies (34). These antibodies present high specificity, since they can only 
interact with a specific and unique substance (10,31). They can be useful to distinguish 
subsets of B-cells or T-cells, being helpful on the identification of different types of 
leukaemia and lymphomas. Monoclonal antibodies are also used to quantify the number 
of B cells, which is important in immune disorders such as Acquired Immune Deficiency 
Syndrome (AIDS) (34). The US Food and Drug Administration has already approved 21 
monoclonal antibody-based therapeutics to treat several human disorders, including 
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cancer, transplant rejection, asthma and auto-immune, cardiovascular and infectious 
diseases (16,23).  
 
1.2.1 - Structure and function of antibodies 
Antibodies contain a structural domain composed of four polypeptides similar to 
many other proteins (9). They are constituted by two identical heavy (H) (~55kDa) chains, 
each carrying covalently attached oligosaccharide groups; and two identical light (L) 
(~25kDa) non-glycosylated chains. The resulting molecule is represented by a schematic 
Y-shaped molecule of ~150kDa (9,10). One heavy and one light chain are joined together 
by disulphide and non-covalent bonds; two heavy chains are joined together by a 
disulphide bond (9,10) (Figure 2). The disulphide bonds, named hinge, have 
approximately 12 amino acids, essentially Pro, Thr and Ser, and are located in a flexible 
region of the heavy chain which is exposed to enzymatic or chemical cleavage with 
papain or pepsin (9,10). This region imparts lateral and rotational movement to the 
antigen binding site, providing the antibody with the ability to interact with the antigen 
(9). The four polypeptide chains contain constant (C) and variable (V) regions that are 
present in the carboxyl and amino terminal portions, respectively. Both heavy and light 
chains contain only a single V region; the light chains comprise a single C region and 
heavy chains contain three C regions (10,29). The H and L-chains of antibodies are 
encoded by two genes, one for the V region and one for the C region. The V region genes 
do not exist in the germline genome, unlike those from the C region; instead, they are 
assembled from banks of genomic DNA segments during the development of the cells. 
The mix-and-much assembly results in a huge diversity of V region genes (30). So, the 
three V regions in both chains of the antibody constitute the epitope binding site or 
complementary-determining regions (CDRs). There is a vast array of coding regions and 
transcription of unique CDRs which are generated by numerous mechanisms like the 
different combination of heavy and light chains, genetic recombination, imprecise joining 
during recombination and high somatic mutation rate. In this line, a huge diversity of 
sequences necessary to bind a diverse spectrum of antigens is created. The antigen-
binding specificity is determined by the physical and chemical properties of its CDR (9). 
The epitope is the antibody binding site in the antigen and is generally composed of 
carbohydrates or proteins since the surface molecules of pathogens are commonly 
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glycoproteins, polysaccharides, glycolipids or  peptidoglycans (9,10,29). The antigen 
effector domains are present on the tail of the molecule (10,29).   
  
Figure 2 – Schematic representation of an antibody structure (35). 
 
Immunoglobulin molecules are bifunctional; one region of the molecule is responsible 
for the binding to the antigen while the other mediates the effector functions (12). Each 
immunoglobulin class has a characteristic type of heavy chain giving rise to diverse 
immunoglobulin sub-classes; the immunoglobulin sub-class is crucial for the 
determination of the type and temporal nature of the immune response (9,12). In 
mammals, there are five immunoglobulin classes: IgG, IgM, IgA, IgD and IgE; and in 
hens there are three classes: IgY, IgM and IgA. In some mammals, IgG and IgA are 
subdivided into sub-classes, referred as isotopes, precisely due to polymorphisms in the 
C regions of the heavy chain (9). In addition, it is important to refer that the carbohydrates 
content of these glycoproteins vary considerably between the different sub-classes, 
ranging from 2-3 % for IgG, to 12-14 % for IgM, IgD and IgE, and which significantly 
influence the immunoglobulins physicochemical properties (12).  
The antibodies activity is affected by variations in pH, salt concentration, presence of 
proteolytic enzymes and other destabilizing factors. However, their structure helps them 
to resist to severe conditions due to the folding of the immunoglobulin chains into a 
compact, stable and unique domain named immunoglobulin domain (29). Despite this 
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stability observed in most antibodies, the antigen binding domain and the effector domain 
can be separated from each other by proteolytic digestion. Papain is capable of 
fragmenting all isotypes into Fab (monovalent for antigen binding) and Fc (effector 
domain) fragments by cleaving the heavy chain above the disulphide bonds that hold them 
together. This cleavage only occurs under physiological pH. On the other hand, pepsin 
can cut the Y molecule below this linkage, leading to different Fab and Fc fragments 
(9,10). These papain and pepsin generated fragments offer insight into structure and 
function of antibodies because they separate the Fab region from the Fc region, which 
mediates effector functions and monocyte binding (12). Figure 3 depicts the enzymatic 
cleavage process of the human IgG.  
 
Figure 3 – Schematic representation of the human IgG enzymatic cleavage by pepsin and papain. The 
human IgG heavy chain is cleaved at positions 234 and 333 to yield the F(ab’)2 and the pFc’ 
fragments. Papain cleaves the molecule at the residue 224, in the hinge region, originating two 
Fab fragments and one Fc fragment. Secondary cleavages give raise do Fc and Fc’ fragments 
(12). 
 
Antibodies are useful tools for passive immunity. Passive immunity represents the 
process of providing pre-formed antibodies to protect the organism against infections or 
other diseases (36). The protection provided is immediate and lasts for several weeks to 
three or four months at most (36,37). The immune system of a neonate is relatively 
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immature. Therefore, maternal antibodies pass to the descendants in order to confer 
natural passive immunity, which is essential for the adaptation of the neonate to the extra 
uterine environment (38,39). The route of transmission of natural passive immunity in 
mammals is a difficult process since the antibodies are enclosed within the uterus of the 
mother  and because of the diversity of structure of the embryonic membranes (40). 
Placenta is the most well-known organ involved in exchanges between the maternal and 
fetal circulation. It keeps the two blood streams separated, allowing the exchange of 
substances of all kind between the fetus and the progenitor circulation (40). In humans, 
maternal antibodies (IgG) are passed from mother to the fetus during pregnancy and to 
the neonate through IgA in the breast milk (38,41). Other mammals obtain their maternal 
antibodies via colostrum which are then transported across the intestinal epithelium of the 
neonate into circulation (37,41). In chickens, natural passive immunity is transmitted 
from the mother to the young birds trough the yolk of the egg, while on the ovary (40). 
On the other hand, acquired passive immunity implies that antigen-specific antibodies are 
obtained from another source, as presented below in Figure 4 (37). It requires the 
collection of antigen-specific antibodies from another source (immunized individuals) 
and their administration on susceptible individuals (36). The first step consists in the 
injection of the animal with the antigen of interest, which can be done by intravenous, 
intraperitoneal, subcutaneous or intracutaneous injections (42). Due to the transient nature 
of the protection provided by passively transferred antibodies, a repeated or continuous 
administration is necessary and thus large amounts of the specific antibodies are required 
(37). In this context, chicken eggs are advantageous in passive immunization applications 
since they are a source of large amounts of antibodies and the recovery of these is carried 
out though a less-invasive technique (37).   
 
Figure 4 – Passive immunization (37). 
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1.2.1 – Hen and mammalian antibodies  
As referred before, antibodies have numerous applications. In clinical practice, 
antibodies are widely used in diagnosis or in immunotherapy in order to neutralize 
pathogens (33,43). Antibody-based immunoassays are the most used type of diagnostic; 
the first major milestone in antibody-based immunoassays was the development of the 
binding assay, using radioisotope and later enzyme-labelled immunoassays (44). Besides, 
these immunoglobulins are also useful in protein science and are frequently employed for 
detection and determination of various antigens, representing one of the fastest growing 
technologies for the analysis of biomolecules  (33,43,44). In general, these immunoassays 
were mostly based on polyclonal antibodies. However, in 1975 Kohler and Milstein (45) 
described the use of monoclonal antibodies in immunoassays. The most frequently chosen 
mammals for polyclonal and monoclonal antibody production are rabbits and mice, 
respectively (13).  
Antibodies are frequently obtained from de blood of animals. However, this practice 
has numerous disadvantages since some of the steps involved in antibody collecting cause 
distress to the animals involved. The collection of blood samples by bleeding, which is a 
prerequisite for antibody preparation, sometimes results in the animal death (13,33,43). 
On the other hand, these antibodies also have disadvantages related with their production 
on an industrial scale due to the difficulty in obtaining large quantities of blood (14). More 
recently, the use of hens instead of mammals for antibodies production has increased 
(13,33). There are three immunoglobulin classes in hens namely: IgA, IgM and IgY. The 
molecular characteristics of hen IgA and IgM are similar to mammalian IgA and IgM 
(13). The structure of IgY, which is the major low molecular weight serum protein in 
oviparous, is similar to mammalian IgG, containing two light and two heavy chains (13).  
The use of  chicken egg for antibodies production represents a much more economical 
and refined source to obtain large quantities of specific antibodies (13,37,46). It enables 
the reduction of the number of animals used while the collection of blood is replaced by 
the collection of eggs, being thus less invasive (13,43,47). The IgY concentration in the 
blood of a chicken is 5-6 mg/mL, whereas in egg yolk it is 10-25 mg/mL (33). Per year, 
an immunized hen produces more than 40g of IgY through eggs, corresponding to the 
amount of IgG produced from 40 rabbits (14). Due to phylogenetic distance between birds 
and mammals, mammalian proteins are often more immunogenic in birds than in 
mammals, resulting in an easier and faster stimulation of antibody synthesis (13,37). IgY 
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can react with many epitopes of mammalian antigens resulting also in an amplification of 
the signals and in a different antibody repertoire (37,48). Because of this genetic distance 
it is further possible to produce antibodies against highly conserved mammalian proteins 
(37). Chicken egg antibodies neither bind to the mammalian or bacterial Fc receptor, 
which could mediate an inflammatory response, and do not activate the complement 
system nor react with the rheumatoid factor, which is an anti-immunoglobulin 
autoantibody found in many different diseases (37,47). In addition, IgY immunoglobulins 
do not react with mammalian IgG or IgM and these lack of cross-reactivity is reflected in 
a great reduction of background and false results in assays using anti-IgG antibodies (49). 
The above-mentioned advantages have a crucial significance in immunodiagnostics. 
Currently, IgY are been used as primary antibodies in techniques such as ELISA, Western 
blotting and immunochemistry and also as secondary antibodies, when combined with 
peroxidase (33).  
Chicken eggs are a preferred antibodies source since these possess properties 
comparable or in some regards better than those of mammalian antibodies (33,46). In 
contrast with mammalian serum, egg yolk contains only a single class of antibodies (IgY) 
that can be isolated from the yolk (37). Nevertheless, there are several disadvantages 
connected to egg yolk, which have been limiting their widespread use (11). In particular, 
egg yolk is a fluid emulsion with a dispersive phase rich in lipoproteins and glycoproteins, 
turning therefore the isolation of IgY difficult to achieve (33). 
 
1.3 - Immunoglobulin Y (IgY)  
During the egg formation, IgY is selectively transferred to the yolk via a specific 
receptor present on the surface of the yolk membrane (33,37). IgA and IgM, similar to 
mammalian IgA and IgM, are secreted in the maturing egg follicle together with other 
proteins and are deposited into the egg white, as presented in Figure 5 (33,37). The 
presence of mammalian equivalents of IgE and IgD was proposed, yet not identified or 
proven in hens (13).  
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Figure 5 – IgY transfer from the blood to the egg yolk, through specific receptors during the egg 
formation. IgA and IgM are deposited into the egg white in the oviduct (37). 
 
The overall structure of IgY is similar to mammalian IgG, with two light (L) and two 
heavy chains. Leslie and Clem (50) proved, in 1969, the existence of profound differences 
between the mammalian and avian IgG, recommending the word IgY for avian IgG. In 
1962, Williams (51) identified the IgY protein as the predominant  and most important ɣ-
globulin in a ɣ-levitin fraction of the yolk. Livetins are a fraction of water soluble proteins  
that  constitute 10 % of the egg yolk dry-matter and include α- , β- and ɣ-livetin (52). 
Among all birds chicken IgY is the most frequently studied, best described and 
characterized (13). 
 
1.3.1 – Molecular properties of IgY 
The general structure of IgY presents two heavy chains (H) with a molecular weight 
of 67-70 kDa each and two light chains (L) with a molecular weight of 25 KDa each 
(13,53). Since the heavy chain of IgY has one constant  domain longer than that on IgG, 
it’s relative molecular weight increases to 6.4 × 10 4 kDa (33). The main difference 
between the two molecules is the number of constant regions in the heavy chains: IgG 
has three C regions (Cγ1-Cγ3), while IgY has four (Cv1-Cv4) (13). The heavy chain of 
IgY does not have a hinge in contrast with the IgG structure, where two of the three 
constant domains are separated by a hinge which gives considerable flexibility to the 
molecule (Figure 5) (43). The absence of this hinge region, in IgY, reduces de mobility 
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of the molecule containing the variable domains (the portion containing the antigen-
binding site) and the intra-molecular forces of IgY are thus weaker than those of 
mammalian IgG (33,53). This affects the cross-linking of a binary complex antigen-
antibody, affecting the ability of IgY to form an immunoprecipitate with antigens (33). 
The regions in IgY near the boundaries of Cv1-Cv2 and Cv2-Cv3, contain proline and 
glycine residues enabling only a limited flexibility (13). The content of the β-sheet 
structure in C domains of IgY is lower than in mammalian IgG; as a result, the 
conformation of IgY is more disordered in comparison to mammalian IgG (53).  
 
Figure 6 – Structure of IgG and IgY (43). 
 
IgY is more hydrophobic than IgG and its isoelectric point is also lower (54). The IgY 
isoelectric point ranges between 5.7 and 7.6, whereas that of IgG is in the range between 
6.1 and 8.5 (13,53,54). Nevertheless, IgY is more sensitive than rabbit IgG to acid 
denaturation (54). Shimizu et al. (55) reported that the activity of IgY was decreased at 
pH 3.5 or lower and almost completely lost at pH 3. These results confirmed 
conformational changes and damage in the Fab portion including the antigen binding site 
(53). The activity of IgY under alkaline conditions do not change until the pH increase 
up to 11, being significantly diminished at pH 12 or higher (55). Regarding the IgY 
proteolysis stability, it largely depends on the nature of the digestion enzymes and on the 
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pH conditions (54). In 1993, Hatta et al. (56) reported that the IgY activity was lost after 
digestion with pepsine. The same group of researchers demonstrated that at pH 5 or higher 
pH values, IgY retained its antigen-binding and cell-agglutinating activities, being highly 
resistant to pepsin digestion (56). However, at pH 4.5 or lower, both activities were lost 
(57). The SDS-PAGE profiles of IgY after incubation with pepsin showed that at pH 2 
IgY was digested to small peptides and no bands corresponding to IgY were detected on 
the polyacrylamide gel, suggesting the complete hydrolysis of the antibodies (56). At pH 
4, IgY digested with pepsin retained is activity at 91 % and 63 % after one hour and four 
hours of incubation, respectively (56). Regarding the trypsin or chymotrypsin digestion, 
Shimizu et al. (57) and Hatta et al. (56) were able to demonstrate that there was a high 
loss of specific IgY activity during passage through the stomach mostly due to the 
activities of these pancreatic proteases (56,57). IgY kept is activity at 39 % and 41 % after 
eight hours of incubation with trypsin or chymotrypsin, respectively (53). The trypsin 
digestion results in a definitive cleavage of the IgY chains whereas the resulting fragments 
of the chymotryptic digestion present higher values of activity (53). Concerning the 
temperature stability, besides being stable at temperatures around the room temperature, 
IgY is also stable at temperatures ranging between 60 ºC and 70 ºC (55,57). However, the 
IgY activity decreased by heating at 70 ºC or higher for 15 minutes and it is denatured 
when exposed to temperatures higher than 75 ºC (58). 
 
1.3.2 – Applications of IgY 
Chicken polyclonal antibodies are applied in many different methods for various 
purposes: as therapeutic reagents, as tools for purification or detection of antigens, in 
diagnostic and as protective agents of passive immunization (54,59–61). IgY was 
demonstrated to work in practically all tested immunological methods that were originally 
developed for mammalian IgG (61). These methods include immunofluorescence, 
immunoenzyme techniques, immunoelectrophoresis, ELISA, western blotting and 
immunohistochemistry, among others (33,49). Since it is possible to conjugate IgY with 
horseradish peroxidase or biotin, the resulting conjugates can be used in common 
immunochemical procedures (62,63). Besides, IgY was already used for immunodection 
of Bortritis-specific invertase in infected grapes (64). The fact that IgY possesses a lower 
pI value than mammalian IgG makes it also usable in rocket electrophoresis to quantify 
immunoglobulins of mammalian sera, namely IgG and IgM (65). The only limitation of 
17 
 
 
using chicken antibodies for this type of assays consists in the lower ability of IgY to 
precipitate antigens. However, this can be overcame by using optimized conditions, such 
as an increase of the ionic strength (33). There is also an increasing interest in the use of 
IgY in immunodiagnostics and immunotherapy owing to its inherent advantages (66). 
The relatively inexpensive production of eggs suggests that hen-egg antibodies could be 
used in cases where a high amount of immunoglobulins is needed to reach the therapeutic 
effect (33). Passive immunization and prophylaxis are relevant fields and mammalian 
antibodies have already been applied for these purposes; but, due to their high cost, they 
were only used to treat emergency cases (33). Hens can be immunized for production of 
antibodies against various antigens, such as viral and bacterial antigens producing 
antigen-specific IgY (37,49,54,66). The use of IgY for passive immunization has been an 
intensively studied research field and its effectiveness has been demonstrated in the 
prevention and treatment of infectious diseases caused by various pathogens in animal 
models, especially those of the intestinal tract (37,49,53). Some studies revealed positive 
results against some pathogens in mice, pigs and calves. Table 1 presents some of these 
positive results (53).  
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Table 1 - Effect of passive immunization by enteric pathogen-specific IgY (53). 
Pathogen Animal 
specie 
Effects References 
Salmonella Mice Preventing and protecting mice challenged 
with S. Enteritidis or S. Typhimurium from 
experimental salmonellosis 
(67) 
Calves Preventing fatal salmonellosis in neonatal 
calves exposed to S. Typhimurium or S. Dublin 
(68,69) 
Laying hens Reducing S. Enteritidis contaminated eggs rate 
in experimentally infected hens 
(70,71) 
Broiler 
chickens 
Reducing caecal colonization and faecal 
shedding in S. Enteritidis challenged chickens 
(72) 
Campylobacter 
jejuni 
Broiler 
chickens 
Inhibiting and Reducing the faecal shedding of 
C. jejuni 
(73) 
Escherichia coli Pigs Preventing, protecting and curing piglets 
infected with E. coli-induced enterotoxernia 
(74–76) 
 Calves Protecting neonatal calves from fatal enteric 
colibacillosis by K99-piliated ETEC 
(77) 
Rabbits Preventing diarrhoea in rabbits challenged with 
ETEC 
(78) 
Rotavirus Mice  Preventing murine rotavirus (MRV), human 
rotavirus (HRV)-induced gastroenteritis and 
HRV-induced gastroenteritis and protecting 
mice from bovine rotavirus (BRV)-induced 
diarrhoea 
(79,80) 
Calves Protecting and preventing BRV-induced 
diarrhoea in neonatal calves 
(81) 
 
Recently, IgY was also reported to be used as an useful tool in cancer research, 
diagnosis and therapy (49). Nevertheless, the applications of IgY are still limited mainly 
due to the prior extraction and purification steps that are difficult to accomplish. To 
overcome these obstacles, the existing methods should be optimised or new techniques 
should be established (15).  
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1.4 – Purification of antibodies  
The production and applications of both monoclonal and polyclonal antibodies have 
been receiving considerable attention in the last few decades, emerging as one of the 
fastest growing fields of biotechnology  (21,82). For diagnosis, antibodies are the ideal 
biological recognition reagents, and thus, are useful in a range of analytical platforms, 
namely western blotting (immunoblotting), immunohistochemistry, 
immunocytochemistry, immunoprecipitation, enzyme linked immunosorbant assay 
(ELISA), antibody microarrays, antibody-imaging, radioimmunoassays, flow cytometric 
analysis, immuno-polymerase chain reactions (IPCRs) and real-time IPCRs (9,83–85). In 
addition, they are also used as a useful tool in immunoaffinity chromatography (35). 
Antibodies are generally isolated from plasma, serum, ascites fluids, cell culture medium, 
egg yolk, plan extracts or bacterial yeast cultures. All of these sources have different 
proteins in addition to antibodies and most of the above-mentioned applications demand 
homogeneous antibody preparations. Hence, an efficient purification of antibodies 
becomes imperative (35). The purification of antibodies can be achieved by a range of 
methodologies based on the specific physical and chemical properties of these molecules, 
such as size, solubility, charge, hydrophobicity and binding affinity (21,35,86). 
Affinity chromatography is the most widely employed method for antibody 
purification and it was first introduced in 1968 by Cuetrecasas and co-workers (87). This 
technique relies on a reversible interaction between the antibody and its specific antigen. 
The specificity of binding is exploited for the selective absorption of the target protein 
from a complex matrix, and it can be eluted by using competitive analogues, denaturing 
agents or other factors, such as pH, ionic strength and polarity (35,87). The successful 
application of this technique depends on a number of favorable characteristics regarding 
the chromatographic matrix and the ligands used (35,87). The matrix should be uniform, 
microporous, hydrophilic, chemically and mechanically stable, selective, exhibit 
minimum non-specific absorption and it should provide a large scale area for the ligand 
attachment (35). The ligand, which also plays a major role in the specificity and stability 
of the system, must have affinity to the target antibody, specificity, immobilization 
feasibility, stability in harsh washing and elution conditions, and retention of the target 
binding capacity after its attachment to the matrix (35). Bispecific ligands, such as 
bacterially derived receptor, antigens and lectins, have been suggested for this purpose. 
The most commonly used ligands for purification of full length antibodies are 
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staphylococcal protein A and streptococcal protein G (21,35,82,86). Protein A is a 
component of the cell surface of Staphylococcus aureus and it is composed of five Ig-
binding domains (E, D, B and C) (35,88). It interacts with antibodies through two distinct 
binding events: the typical binding site on the Fc portion of human IgG1, IgG2, and IgG4, 
and the alternate binding site found on the Fab portion of human IgG, IgM, IgA, and IgE 
(88). Protein G is isolated from Streptococcus and it binds strongly to the Fc region on 
the IgG (35). Due to the protein A superior stability and binding capacity, when compared 
to protein G, it is often preferred for industrial-level purifications of IgG (35,86). Besides, 
protein G binds to albumin, α2- macroglobulin and kinogen, along with IgG, leading to a 
reduced purification efficiency (89). Despite the popularity of these ligands, they have 
some disadvantages, including high manufacturing and processing costs, instability, 
potential for the ligand to leak from the column, storage, are labor-intensive, and 
difficulty in sterilization steps. Besides, the majority of biospecific ligands are produced 
in bacteria from which there is an attendant risk of contaminants, such as viruses, 
pyrogens and DNA (35). Other chromatographic techniques have been applied for 
antibodies purification, namely hydrophobic charge induction chromatography (HCIC), 
thiophilic affinity chromatography (TAC) and immobilized metal affinity 
chromatography (IMAC). HCIC is based on the hydrophobic interactions between the 
ligand and the target and it is achieved under physiological conditions (35,90). The 
desorption step is then based on electrostatic charge repulsions and it is accomplished by 
reducing the pH of the mobile phase. Under acidic conditions both, the ligand and the 
target molecule have positive charge and the binding is disrupted (35,90). This technique 
has already been successfully applied in the capture and purification of IgG (90). TAC is 
another method used for antibodies purification; it uses sulfur-containing ligands attached 
to a matrix which binds antibodies in the presence of high concentrations of salts that 
induce the exposition of the hydrophobic regions of proteins (35). Thiophilic gels are the 
most commonly used absorbents, based on a reaction between divinylsulfone and 2-
mercaptoethanol. The structure of the immobilized ligand can be written as agarose-
CH2CH2SO2CH2CH2SCH2CH2OH. As the aforementioned technique, thiophilic 
chromatography as already been used as a method for purification of IgG from different 
species (91,92). In IMAC, the capacity of biomolecules with exposed His, Cys, Ser, Glu, 
Asp and Trp residues is exploited for the design of ligands, which are attached to a 
covalently linked chelating compound and a spacer group (35). This technique is reported 
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to be used in the purification of antibodies from different species and classes namely the 
IgG from human plasma (93).  
Despite all these encouraging results, these techniques are laborious and of high cost. 
These methods usually involve more than one step of purification to remove the 
remaining host cell proteins, DNA, possible leached Protein A and IgG aggregates (21). 
In order to provide an adequate level of viral clearance, a viral inactivation step (low pH 
hold) and a viral filtration step are sometimes needed (21,94). Furthermore, in each step, 
some quantity of the target molecule can be lost, resulting in low yields (94). In order to 
ensure that downstream costs do not cancel out the expected upstream gain, the 
development of effective and economical purification methods is a crucial demand (82). 
Recently, the use of ABS has been suggested as an interesting alternative to the traditional 
purification schemes, since clarification, concentration and purification can be combined 
in only one operation, while using a water-rich biocompatible environment, as discussed 
below (21,82). 
 
1.4.1 – IgY extraction and purification 
Nowadays, there is an increasing interest in chicken egg yolk for the production of 
polyclonal antibodies (13,95). Chicken egg yolk is an interesting source of IgY, a specific 
antibody with potential applications in many fields (33). Despite all the advantages IgY 
is commercially produced only in small quantities and with high production costs, which 
are mainly due to the several steps required for IgY purification (96). In addition, IgY do 
not bind to protein-A or protein-G, which are the most widely used affinity ligands for 
the purification of IgG from biological fluids, as mentioned before (97).  Egg contains 
approximately 50 % of water and its dry weight is made up of 2/3 of lipids and 1/3 of 
proteins. The proteins are divided into four fractions: lipovitellin, phosvitin, low-density 
lipoproteins and livetins (the IgY is a subclass of livetins) (20).  
IgY purification schemes involve extraction of the water-soluble fraction followed by 
several purification steps (96).  The purification of IgY usually proceeds in two stages: i) 
separation of the water-soluble fraction containing IgY from the lipidic fraction, which is 
mainly composed of lipids and lipoproteins; and ii) isolation of IgY from other water 
soluble proteins (15,33,98). The first step is usually carried out by a simple water dilution 
method (96). However, many techniques have been developed and tested to remove the 
lipophilic yolk components from the crude IgY extract (98). Polyethylene glycol (PEG), 
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dextran sulphate, algina, caprylic acid and other organic solvents were investigated by a 
simple dilution of the yolk, or by a freezing-thawing approach of the diluted yolk, in order 
to form lipid aggregates large enough to be removed by centrifugation and filtration (98). 
Some methods, such as ultracentrifugation, hydrophobic or affinity chromatography were 
also investigated as a first purification step (47,98). For a large scale production, the 
limiting step is usually the separation of the water soluble proteins from the lipids and 
other hydrophobic substances (20,47,98). The second stage comprises the recovery of the 
pure IgY fraction from the WSPF of the yolk (98). Many methods have been described 
for such a purpose, with most of them involving most of them involving salt precipitation 
or chromatographic techniques (99).   
Jenesenius et al. (100) introduced a new method based on the water dilution of egg 
yolk as a simplification of the dextran sulphate precipitation method. After freezing and 
thawing, at low ionic strength and at a pH 7 or lower, the yolk lipids aggregate and can 
be removed by centrifugation. The freeze and thaw step was additionally substituted by 
water dilution, at pH 6 and pH 7, by Kwan and co-workers (101). The lowering of the pH 
values and increasing of the dilution ratio strongly contributed to a higher lipids removal 
(15,101). The study of the aqueous dilution method was performed in detail by Akita and 
Nakai, in 1992 (102). Their results showed that with pH values below 5.0, the recovery 
of IgY decreased from 93 to 75 %, while a pH increase up to 6.6 caused even a more 
dramatic loss (55 %). So, the optimum pH values were established between 5-5.2, 
corresponding to the maximal IgY’s recoveries (102). Polson et al. (103) were the first to 
introduce the extraction of IgY from egg yolk using PEG as a precipitation agent for the 
lipidic fraction. This method was rejected later, mainly due to the fact that it is time 
consuming and the yields obtained were very low (15). Several studies were carried out 
using cadmium sulphate, zinc sulphate and ammonium sulphate for inducing the IgY 
precipitation (99,104). The results obtained by Gazin Bizanova et al. (99), in 2003, 
revealed that IgY preparations purified with ammonium sulphate contain a higher total 
amount of proteins than those purified by the other two salts. However, regarding the 
purity of IgY, the results were not satisfactory (99). In 1981, Jensenius et al. (105), made 
use of the interaction between the anionic polysaccharide dextran sulphate with egg yolk 
lipoproteins to obtain the IgY fraction. Nevertheless, dextran sulphate is very expensive, 
making the method unviable in a large scale. Natural gums, like xanthan and carrageenan, 
were also tested and seemed to be able to remove most of the lipids, while maintaining 
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an acceptable protein recovery (106). Recently, Chang and co-workers (107), used λ-
carregeenan, alginate, pectin and Na-carboxymethyl cellulose to recover IgY from 
adequately diluted yolks in a single step process. The optimum isolation conditions were 
determined at pH 5 and the best IgY recovery was performed using pectin (20.87 % 
purity) (15,107). With the goal of developing a new and pioneering affinity purification 
technique, Verdorliva et al. (97), studied the TG19318 ability to capture IgY directly from 
the water soluble extract. Protein A Mimetic TG19318 is a new synthetic ligand which 
binds specifically and selectively to the constant portion of immunoglobulins (97). The 
results showed a yield value of 10.2 % and a purity > 90 % (97). Several commercial kits 
are also available for IgY purification. Two of the most used kits are Thermo Pierce's 
Eggcellent™ and Promega's EGGstract®. They are based on a dilipidation step followed 
by a protein purification/precipitation step. However, in spite of both kits are able to 
produce reasonably pure IgY (70-90 %) they are particularly expensive given the yield of 
IgY produced (47). It should be pointed that, in most of the above mentioned studies 
sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) was used to 
confirm the presence of IgY at the different steps of the isolation process (20,46,102,108). 
The stained gels revealed the decreasing number of proteins in the mixture at each 
purification step while evaluating the purity of IgY by the two major protein bands 
corresponding to the reduced heavy and light chains of IgY (20,46). 
A previous study has proposed the use of ABS, instead of the previously referred 
techniques, for IgY extraction and purification (20). ABS could be used to separate IgY 
into one phase and lipoproteins into another, and as the primary purification step. Then, 
IgY can be extracted from the IgY-rich-phase by affinity chromatography, or the IgY-
fraction can be extracted by selective precipitation or T-gel chromatography in a 
secondary purification step (20). 
 
1.5 – Extraction and purification of biomolecules using aqueous biphasic systems 
(ABS) 
The extraction and purification of biomolecules generally encompasses four stages 
namely recovery, isolation, purification and polishing (94). The use of liquid-liquid 
extraction techniques as the first downstream purification step allows the separation and 
concentration of the target proteins simultaneously (16). Liquid-liquid extraction using 
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ABS is a powerful non-chromatographic technique that has been suggested as an 
attractive alternative as a primary stage unit operation in the downstream processing of 
biological products, such as cells, virus, RNA, plasmids, nucleic acids and proteins 
(16,22,94). These systems are formed when two mutually incompatible hydrophilic 
solutes, usually two polymers or a polymer and a salt, are dissolved in water above a 
certain concentration (94,109). The process of aqueous two phase partition of 
biomolecules was firstly introduced by Albertson (110), based on ABS formed by PEG, 
potassium phosphate (K2HPO4) and water, and PEG, dextran and water (110,111). This 
discovery was the boost to the use of these systems as an important separation technique 
in the downstream processing of biomolecules (2,94). ABS have many advantages since 
they provide a suitable environment (water-rich) to maintain the proteins integrity and 
biological activity (16,94). ABS are also a fast separation technique with weak 
denaturation effects and do not use volatile and hazardous organic compounds (23,94). 
Liquid-liquid extraction in ABS is also a relatively inexpensive technique, is easily 
operated and scaledup, it presents high resolution capacity and allows clarification, 
separation, purification and concentration in just one step (22,94,109). 
The partitioning of a target compound in ABS depends on a number of parameters, 
which include the physicochemical properties of the system, the nature and structure of 
target solute and the interactions between the last and the phase-forming components of 
ABS (2). The properties of the system comprise the pH value, ionic strength, and type of 
the phase-forming components, while the nature of the target solute includes its charge, 
molecular weight, hydrophobicity and conformational characteristics (2,94). 
Benavides and Rito-Palomares (112,113) suggested the division of the ABS process 
into four main stages: initial physicochemical characterization of the feedstock, selection 
of the adequate ABS, selection of the system parameters and evaluation of the influence 
of the process parameters upon product recovery/purity. Once the product of interest is 
characterized, the phase-forming components of the ABS must be selected (2). When the 
partition of the molecules is not one-sided it is possible to increase the process yield and 
selectivity by the addition of neutral salts or affinity ligands for the target protein (2,23). 
In polymer-polymer systems, the addition of an electrolyte and its partitioning through 
the phases may alter the partition of the target molecule. The more hydrophilic phase is 
rich in ions such as Li+, Na+, NH4
+, Ca2+, Mg2+, F-, SO4
2-, CO3
2-,PO4
3− and CH3COO
−; on 
the other hand, more hydrophobic phases are rich in ions such as K+, Rb+, Cs+, Cl−, Br−, 
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I−, SCN−, NO3
− and ClO4
− (2). In polymer-salt systems, the addition of neutral salts, such 
as NaCl, may increase the hydrophobicity difference between the phases due to the 
decrease of the amount of bounded water, resulting in an exposure of the hydrophobic 
domains on the protein surface, which will promote hydrophobic interactions with the 
polymer phase (2). The addition of selective ligands is mainly used in polymer-polymer 
ABS and it can make the extraction in ABS more predictable and selective, improving 
the partitioning of the target molecule (2). PEG is frequently used for derivatization 
mainly because of its terminal hydroxyl groups which can be functionalized. A large 
variety of functionalized groups can be covalently attached to PEG and have been largely 
investigated to increase the affinity between the polymer and the target protein (2,23).  
ABS have unique phase diagrams under a particular set of conditions, namely pH and 
temperature. They can provide information related with the concentration of the phase 
components required to form two phases, the concentration of the phase components in 
the top and bottom phases, and the ratio of the phase volumes. A typical ABS diagram 
has a binodal curve (TBC), which divides a region of components concentrations that 
form two immiscible aqueous phases from those that form one phase. Usually, the region 
which allows the formation of two immiscible phases is the one above the binodal curve 
(Figure 7) (94). The three global mixtures, X, Y and Z, differ in their initial compositions 
and volume ratios, but all have the same composition at the top phase (TIL,Tsalt) and at the 
bottom phase (BIL,Bsalt). This similarity is mainly due to the fact that they are lying on the 
same tie-line (TL), whose end points are determined by the equilibrium phase 
composition. The length of the tie-line (TLL)  has the same units as the component 
concentrations and defines the difference on the compositions among the phases (94). 
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Figure 7 – ABS phase diagram binodal curve. TCB = binodal curve; C=critical point; TB = tie-line; 
T=composition of the top phase; B = composition of the bottom phase; X, Y and Z = mixture 
compositions at the biphasic region (94). 
 
Nowadays, ABS are extensively used as an alternative to the existing 
chromatographic techniques to purify biopharmaceuticals, such as monoclonal 
antibodies, growth factors and hormones (94). The use of ABS-based extractions in the 
downstream processing of monoclonal antibodies was reported in 1996, by Zijlstra and 
co-workers (114), who have used a functionalised PEG/Dextran system to recover IgG 
from hybridoma cell supernatants. Meanwhile, another research team used polymer-salt 
based ABS to recover IgG from hybridoma cell supernatants (115). In 2007, Rosa et al. 
(116) proved the viability of using ABS for the purification of human antibodies from a 
protein mixture containing albumin and myoglobin. They achieved a recovery yield of 
101 % and a purity of 99 % using an ABS composed of 8 wt% of PEG, 10 wt% of a buffer 
composed of K2HPO4 and NaH2PO4 and 15 wt % of NaCl (116). The same research team 
also optimized the method of purifying IgG from Chinese Hamster Ovary (CHO) using 
an ABS constituted by 12 wt % of PEG, 10 wt % of a buffer composed of K2HPO4 and 
NaH2PO4 and 15 wt % of NaCl at pH 6, with a recovery of 88 % (16). Table 2 shows 
some of the developed ABS and their successful application in biopharmaceuticals 
purification. 
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Table 2 – Aqueous two-phase extraction/purification of biopharmaceuticals (2). 
Biopharmaceutical Production 
source 
ABS Recovery 
yield (%) 
Purity 
(%) 
References 
Monoclonal Antibody 
(human IgG) 
Chinese 
hamster 
ovary cells 
PEG/ K2HPO4 
PEG/ NaH2PO4 
PEG/dextran 
PEG-
(COOH)2/dextra
n EOPO/dextran 
PEG/ HOC 
(COONa)(CH2C
OONa)2. 2H2O 
88 
96 
 
82 
85 
97 
- 
95 
 
96 
88 
76 
(16,21,24,82
,117) 
Human Interleukin-18 
binding protein (IL-
18BP) 
Chinese 
hamster 
ovary cells 
PEG/ (Na2)SO4 98 92 (118) 
Human monoclonal 
anti-human 
immunodeficiency virus 
(HIV) 2F5 
Transgenic 
tobacco 
extract 
PEG/ K2HPO4 
PEG/ NaH2PO4 
95 - (119) 
Human growth 
hormone (hGH) 
Escherichia 
col 
EOPO/starch 70 - (120) 
Human growth 
hormone antagonist 
E. coli PEG/ 
(NH4)2SO4 
83 - (121) 
Human insulin-like 
growth factor I (IGF-I) 
E. coli PEG/Na2SO4 70 97 (122) 
Monoclonal antibody 
(immunoglobulin G) 
Hybridoma 
cells 
PEG/KH2PO4 
PEG/K2HPO4 
PEG/ HOC 
(COONa)(CH2C
OONa)2. 2H2O 
90 
99 
- 
96 
(82,123) 
Hepatitis B surface 
antigen (HBsAg) 
Yeast cells PEG/ 
(NH4)2SO4 
89 
 
- (124) 
 
1.5.1– ABS using ionic liquids (ILs) 
In 2003 Rogers and co-workers (26) proposed a novel approach to create ABS with 
the use of ionic liquids (ILs).  ILs are a new class of purely ionic salt-like materials that 
are liquid at low temperatures (19,125,126). Their low melting temperatures are due to 
the large size of their ions which leads to a diffuse charge. As a result, they present 
reduced electrostatic forces that make difficult the formation of a regular crystalline 
28 
 
 
structure, and therefore, they can be liquid at or near room temperature (19). The focal 
interest in ILs is due to their generally unique combination of physicochemical properties, 
such as a negligible vapor pressure, null flammability, high ionic conductivity, as well as 
high thermal and electrochemical stabilities. The fact that ILs present non-flammability 
and negligible volatility contributes to their epithet as “green solvents”. Nevertheless, the 
main advantage of using ILs in ABS relays on their tailored solvation/extraction ability 
(19,126,127). The ability to tailor the polarities of the ILs in ABS formation by the proper 
manipulation of cation/anion design and their combination is the major benefit of IL-
based ABS given the difficulty of overcoming the limited polarity range of polymer-based 
ABS. In polymer-based ABS the difference of polarities between the phases is restricted, 
which have been preventing a vast use of these systems for extraction and purification 
purposes. Due to their tunability, ILs can cover the whole hydrophilicity-hydrophobicity 
range (19). The use of ILs in conventional systems provide tailored and optimized 
extractions by a proper choice of the IL. Moreover, IL-based ABS are substantially less 
viscous than typically polymer-based ABS and usually display faster phase separation 
rates (19,128). Therefore, these encouraging properties have led to the research on ILs as 
alternative phase-forming components of ABS (126). The most studied ILs are the 
nitrogen-based and their general cation chemical structures are presented below (Figure 
8). 
 
Figure 8 - Chemical structures of the nitrogen-based cations of ILs 
 
In the past decade, the extraction of biomolecules using IL-based ABS has been 
extensively investigated (126,127,129–132). However, few reports are found concerning 
the extraction of proteins and enzymes (133). Proteins are either insoluble or their 
solubility is very low in hydrophobic ILs and the inactivation of enzymes is a recurrent 
scenario in pure ILs (133,134). ABS composed of ILs and salts were suggested as a good 
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alternative for solving these problems since a large amount of water is introduced (134).  
The extraction of proteins by means of IL-based ABS was firstly achieved by Du et al. 
(133) using a ABS formed by 1-butyl-3-methylimidazolium chloride ([C4mim]Cl) + 
K2HPO4. Later on, several authors employed IL-based ABS for the extraction of other 
proteins and enzymes, such as bovine serum albumin, trypsin, lysozyme, myoglobin, 
cytochrome c, γ-globulins, hemoglobin, peroxidase, ovalbumin and horseradish 
peroxidase (17,26,133–135).  
The stability of proteins is strongly affected by the proton activity of the solution, and, 
consequently by its pH (25,136). It has been accepted that salt ions exert their effects 
indirectly by affecting the protein structure, enzyme activity and protein crystallization 
(25). Recent results revealed that, in some cases, there is a direct interaction between the 
protein and the salt ions (137). However, adding a buffer into aqueous IL solutions, will 
not provide an adequate pH control since the ILs acidity or basicity could swamp the 
buffer effect. The pH can be however adjusted to optimum values by the addition of 
proper ILs with buffer capacity (25). Good and co-workers (138) have described five new 
biological buffers, namely 3-chloro-2-hydroxypropanesulfonic acid, N-[1,3-dihydroxy-
2-(hydroxymethyl)-2-propanyl]glycine (Tricine), [N-bis(hydroxyethyl)amino]-2-
hydroxy propane sulfonic acid, 3-{[1,3-dihydroxy-2-(hydroxymethyl)-2-
propanyl]amino}-1-propanesulfonic acid (TAPS), N-hydroxyethyl piperazine-N'-2-
hydroxy propane sulfonic acid and piperazine-N,N'-bis(2 hydroxy propane sulfonic 
acid)dehydrate. Good’s buffers (GBs), which are zwitterionic amino acid derivatives, can 
be used as anion or cation radicals of ILs still covering the physiological pH range (6 to 
10), leading thus to the creation of a new class of ILs: Good’s buffers ionic liquids (GB-
ILs) (138). Either GBs or IL-derived GBs have demonstrated to be enhanced protein 
structure stabilizers (25). 
This type of GB-ILs was also used in this work, and these were already shown to be 
able to maintain the protein structure while leading to high extraction efficiencies when 
employed as phase-forming components of ABS ( bovine serum albumin was used as a 
model protein) (25,136). Moreover, in a recent study by Taha et al. (139), the same GBs 
anions were combined with the cholinium cations, and these were employed to create 
ABS with a polymer (PEG 400) and further applied in the extraction and purification of 
IgY. Extraction efficiencies of the water-soluble fraction of proteins, ranging between 79 
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and 94 % were achieved in a single step, while the IgY purification was still far from 
being completely achieved (139).  
In the current work, GB-ILs with anions derived from Tricine, 2-{[1,3-dihydroxy-2-
(hydroxymethyl)-2-propanyl]amino}ethanesulfonic acid (TES), N-cyclohexyl-2-
aminoethanesulfonic acid (CHES), N-cyclohexyl-2-aminoethanesulfonic acid (HEPES), 
and 2-(N-morpholino)ethanesulfonic acid (MES) combined with tetrabutylammonium 
([N4444]
+) and tetrabutylphosphonium ([P4444]
+) cations were investigated. The 
synthetized GB-ILs were at first combined with C6H5K3O7 for the ABS formation, their 
phase diagrams were ascertained and the extraction experiments were performed, aiming 
the development of an alternative platform for the selective extraction and purification of 
the IgY from the egg yolk.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2. Purification of IgY using Good’s 
buffers ionic liquids  (GB-ILs) + 
C6H5K3O7 ABS  
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2.1. Experimental section 
 2.1.1. Chemicals  
Fresh eggs were periodically provided from Dr. Ricardo Pires from Biocant, located 
in Cantanhede, Portugal.  
The material required for the ILs synthesis, namely the buffers CHES (purity > 99 wt 
%), HEPES (purity > 99.5 wt %), MES (purity > 99 wt %), Tricine (purity > 99 wt %), 
and TES (purity > 99 wt %), as well as the hydroxide-based compounds, [P4444][OH] (40 
wt % in H2O) and [N4444][OH] (40 wt % in H2O) were purchased from Sigma–Aldrich.  
The material requires to perform the SDS-PAGE analysis comprises: 
tris(hydroxymethyl)aminomethane, PA from Pronalab; sodium dodecyl sulfate, SDS (> 
98.5 wt % pure) andglycerol, 99.5 wt % pure, from Sigma-Aldrich; bromophenol blue 
and acid acetic, 99.8 wt % pure, from Merck; dithiothreitol, DTT (99 wt % pure), from 
Acros; and methanol, HPLC grade, from Fisher Scientific. The Amersham ECLGel Box, 
the Amersham ECL Running Buffer (10X), the Amersham ECL Gel 4-20 %, 10 wells, 
and the Full-Range Rainbow Molecular Weight Marker were acquired from GE 
Healthcare. The Coomassie Brilliant Blue G-250 was purchased from Sigma-Aldrich. 
Citrate tribasic monohydrate (C6H5K3O7·H2O, purity ≥ 99 wt %), sodium phosphate 
monobasic (NaH2PO4, purity: 99 – 100.5 %), sodium phosphate dibasic heptahydrate 
(Na2HPO4∙7H2O, purity: 98.2 – 102.0 %) and sodium chloride (NaCl) were obtained from 
Sigma–Aldrich. The mixture composed of dimethyl sulfoxide-d6 (DMSO D6) and 0.03 
% v/v tetramethylsilane (TMS), purity > 99.8 wt % was purchased from Euriso-top. 
The water employed was double distilled, passed through a reverse osmosis system 
and treated with a Milli-Q plus 185 water purification apparatus. 
 
2.2. Experimental procedure 
2.2.1. Synthesis and characterization of the GB-ILs 
The GB-ILs were synthesized via neutralization of the base with the proper acid. An 
excess of an equimolar aqueous solution (1:1.05) of buffer was added drop-wise to the 
tetrabutylphosphonium or tetrabutylammonium hydroxide solutions. By way of example, 
the CHES buffer was added dropwise into an aqueous solution of tetrabutylphosphonium 
hydroxide. The mixture was stirred continuously for at least 24h at room temperature (≈ 
25 ± 1) °C. The anion source (1.05 equivalents of acid) was added to an aqueous solution 
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of [P4444][OH] (1 equivalent, 40 wt % in water) and the mixture was stirred at room 
temperature for at least 24h to produce the ionic liquid and water as by-product. The 
mixture was evaporated at 50-60 ºC under reduced pressure giving rise to a viscous liquid. 
A mixture of acetonitrile and methanol (1:1, v:v) was added drop-wise to the viscous 
liquid and then stirred for at least 1h at room temperature. The mixture was filtered to 
remove any excess buffer. The solvent mixture was evaporated and the GB-IL product 
was dried in vacuum (10 Pa) for 4 days at 50-60 ºC (25). The water content in each GB-
IL was measured by Karl–Fischer (KF) titration, using a KF coulometer (Metrohm Ltd., 
model 831). The chemical structures of the GB-ILs were confirmed by 1H and 13C NMR 
spectroscopy (Bruker AMX 300) operating at 300.13 and 75.47 MHz, respectively. 
Chemical shifts are expressed in δ (ppm) using TMS as internal reference and D2O as 
deuterated solvent. The synthesized ILs synthetized in this work showed high purity level 
without signs of decomposition.  
 
2.2.2. Phase diagrams and tie-lines 
The binodal curve of each ABS was determined through the cloud point titration 
method at (25 ± 1) °C and atmospheric pressure. This procedure was already validated in 
previous reports, although it was validated in this work with the phase diagram of the 
ABS formed by [C4mim]Cl + K3PO4 + water. The results obtained in this work are in 
close agreement with literature data (140) and are shown in Appendix A – Figure A. 1. 
In summary, an aqueous salt solution was added drop-wise to the IL solution until the 
detection of a cloudy biphasic solution, followed by the drop-wise addition of water until 
the detection of a monophasic region, characterized by a clear and limpid solution. The 
drop wise addition was carried out under constant stirring. The ternary systems 
composition were determined by weight of all the components added within an uncertain 
of ± 10-4 g.  In particular, for the systems composed of [N4444][HEPES], [N4444][MES], 
[N4444][TES] + C6H5K3O7 + water, the turbidimetric method was used (141). Various 
mixtures at the biphasic region were initially prepared, and then ultra-pure water was 
added until the detection of a clear and limpid solution (monophasic region), under 
constant stirring. Each mixture correspond to one point of the binodal curve. The mixture 
compositions were gravimetrically determined within ± 10 -4 g and at (25 ± 1) °C.  
The TLs were determined by a gravimetric method originally described by Merchuk 
et al. (142). A previous selected mixture, at the biphasic region, was gravimetrically 
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prepared and then vigorously stirred. The mixture was then submitted to centrifugation 
for 15 min, at 5000 rpm, at controlled temperature (25 ± 1) ºC. After centrifugation the 
mixture was left in the equilibrium for more 10 min at (25 ± 1) °C, in order to guarantee 
the equilibrium of the coexisting phases. Then, each phase was separated and the top and 
bottom phases were weighted. Finally, each individual TL was determined by the 
application of the lever-arm rule. The experimental binodal curves were fitted using 
Equation 1 (142), 
 
[IL] = Aexp[(B[Salt]0,5) − (C[Salt]3)]       (1) 
where [IL] and [Salt] are the IL and salt weight fractions percentages, respectively, and 
A, B and C are fitted constants obtained by least-squares regression. 
For the determination of the TLs the following system of four equations (Equations 2 
to 5) was used to estimate the concentration of IL and salt at each phase ([IL]IL, [IL]Salt, 
[Salt]Salt and [Salt]IL), 
  
[IL]IL = Aexp[(B[Salt]Salt
0.5 ) − (C[Salt]Salt
3 )]     (2) 
 
[IL]Salt = Aexp[(B[Salt]Salt
0.5 ) − (C[Salt]Salt
3 )]     (3) 
[IL]IL =  
[IL] M
α
− (
1−α
α
 ) [IL]Salt        (4) 
[Salt]IL =  
[Salt]M 
α
− (
1−α
α
 ) [Salt]Salt       (5) 
where the subscripts Salt and IL designate the Salt- and IL-rich phases, respectively, and 
M is the initial mixture composition. The parameter α is the ratio between the weight of 
the top phase and the total weight of the mixture. The solution of the described system 
provides the concentration of the IL and salt in the top and bottom phases.  
In order to calculate each the tie-line length (TLL) Equation 6 was applied, 
 
TLL =  √([salt]IL − [salt]salt)2 + ([IL]IL − [IL]salt)2     (6) 
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The correlation parameters of Equation 1 were determined using the software 
Sigmaplot.v11.0, while the compositions of the top and bottom phases, were determined 
using the software Matlab R2013a.  
All the calculations considering the mass fraction or molality of the citrate-based salt 
were carried out discounting the complexed water. 
 
2.2.4. Purification of IgY using GB-ILs + C6H5K3O7 ABS 
The water soluble protein fraction (WSPF) of egg yolk was prepared from fresh eggs, 
following a protocol described in literature (143), and then applied in the subsequent 
purification step. The ternary mixtures compositions were chosen based on the phase 
diagrams determined for each GB-IL + C6H5K3O7 + water system. A ternary mixture was 
prepared, within the biphasic region, using a common composition of IL (20 wt %) and 
variable concentrations of salt (from 13.5 to 30 wt %) to achieve a similar TLL (with 
values within 39.6 ≥ TLL ≤ 44.3 for systems composed of [P4444][GB] and values within 
39.1 ≥ TLL ≤ 58.1 for those composed of [N4444][GB]). 
Each mixture was vigorously stirred and left to equilibrate for at least 3 h, at (25 ± 1) 
°C, to achieve a complete IgY partitioning and other contaminant proteins between the 
two phases. 
In all the ternary mixtures evaluated, the IL-rich aqueous phase is the top phase, while 
the bottom phase is mainly composed of salt and water.  
The extraction yield of IgY was defined by the ratio between the mass of IgY in the 
top phase and the total mass of IgY initially added to the system by the application of 
Equation 7, 
 
YieldIgY= 
mIgY (top phase)
m IgY (WSPF)
        (7) 
 
2.2.3. pH measurements 
The pH values of both the IL-rich and C6H5K3O7-rich aqueous phases were measured 
at (25 ± 1) ºC using a METTLER TOLEDO SevenMulti pH meter within an uncertainty 
of ± 0.02. 
 
 
37 
 
 
2.2.5. Size-exclusion HPLC (SE-HPLC) 
After a careful separation of the phases, the SE-HPLC technique was used with the 
aim of quantifying the amount of each protein in each phase. A calibration curve was 
specially determined for this purpose (Appendix B - Figure B. 1). The IgY used to prepare 
the calibration curve was purified using the commercial kit EggsPure IgY. A phosphate 
buffer solution (1000 mL) was prepared using 47 mL of a Solution A (27.8 g NaH2PO4), 
203 mL of a Solution B (53.65 g Na2HPO4∙7H2O) and 35 g of NaCl. Each phase was 
diluted at a 1:9 (v:v) ratio in the phosphate buffer solution before injection. A Chromaster 
HPLC (VWR Hitachi) was used for IgY quantification. The SE-HPLC was performed on 
an analytical column Shodex Protein KW- 802.5 (8 mm x 300 mm). A 100 mM phosphate 
buffer + NaCl 0.3 M was run isocratically with a flow rate of 0.5 mL.min-1. The column 
oven and autosampler temperatures were kept at 25 ºC and at 10 ºC, respectively. The 
injection volume was 25 µL. The wavelength was set at 280 nm using a DAD detector. 
The obtained chromatograms were treated and analyzed using the OriginPro8 software.   
 
2.2.6. Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) 
The proteins profiles of the obtained aqueous rich phases, as well as the quantification 
of IgY in each phase, were determined by SDS-PAGE. All samples were diluted so that 
the amount of protein in each gel lane was about 0.5 μg. This amount was predicted taking 
into account the HPLC quantification of the total amount of proteins in each phase. 
Samples of the bottom and top phases of each ABS were diluted in the order of 1:1 (v:v) 
in a dissociation sample buffer constituted by 2.5 mL of 0.5 M Tris-HCl pH 6.8, 4.0 mL 
of 10 % (w:v) SDS solution, 2.0 mL of glycerol, 2.0 mg of bromophenol blue and 310 
mg of dithiothreitol (DTT). This overall solution was heated at 95 ºC for 5 min, to reduce 
the disulphide linkages and denature the proteins. This step overcomes some forms of the 
tertiary protein folding and breaks up the quaternary proteins structure. Electrophoresis 
was run on polyacrylamide gels (stacking: 4 % and resolving: 20 %) with a running buffer 
consisting of 250 mM Tris HCl, 1.92 M glycine, and 1 % SDS. The gels were stained 
with a solution of Coomassie Brilliant Blue G-250 0.1 % (w:v), methanol 50 % (v:v), 
acetic acid 7 % (v:v) and water 42.9 % (v:v), in an orbital shaker at a moderate speed 
overnight at room temperature. The distaining of the gel was done using a solution 
containing acetic acid 7 % (v:v), methanol 20 % (v:v) and water 73 % (v:v) in an orbital 
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shaker at a moderate speed until removing all the excess of dye. SDS-PAGE molecular 
weight standards, marker molecular weight full-range (VWR), were used as protein 
standards.  
A calibration curve by SDS-PAGE was also established for the IgY quantification 
(Appendix C - Figure C. 2). The IgY used to prepared the calibration curve was purified 
using the commercial kit EggsPure IgY. The scanning of the SDS-PAGE electrophoresis 
gels was done using the GenoSmart2 image capturing system and the quantification was 
achieved through the evaluation of the IgY light chain band intensity, using the GenoSoft 
software, both from VWR. 
 
2.2.7 – Molecular docking  
The molecular docking between IgY-Fc and the GB-IL cations was performed using 
the Auto-dock Tools vina 1.5.4 program (144). The crystal structure of IgY-Fc (2W59) 
was used in the docking (145). The natural bond orbital (NBO) charges for the GB cations 
in water phase were used. The center of the grid in the x, y, z axes was (-17.141 × -8.262 
× 16.727) Å and the grid dimension was (78 × 70 × 84) Å. 
 
2.2.8 – Fourier transform infrared spectroscopy (FT-IR) 
The FT-IR spectra were recorded using a Perkin Elmer Spectrum Bx 
spectrophotometer, with a resolution of 4 cm-1 and 32 scans. The FTIR analysis was 
performed using the WSPF sample, as well as the aqueous samples from the IL-rich phase 
of each one of the studied ABS, containing proteins from the WSPF. The spectra were 
obtained in the wavelength range from 1700 to 1500 cm-1, in a room under controlled 
humidity (35 %) and temperature (23 ºC). The PeakFit Version 4.05 was used for the 
spectra evaluation.  
 
2.3. Results and discussion  
2.3.1. Characterization of the synthetized GB-ILs 
The NMR chaterization data of each GB-IL are presented below: 
[P4444][CHES]: From CHES buffer (47.2 mmol), this compound was obtained as a 
translucent viscous liquid. Water content < 0.05 wt %. 1H NMR (300 MHz, D2O/TSP): 
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2.76 (m, 2H), 2.50-2.52 (m, 1H), 2.02 (m, 8H), 1.37-1.45 (m, 16H,), 0.94 (m, 10H), 0.92 
(t, 12H). 
[P4444][HEPES]: From HEPES buffer (44.3 mmol), this compound was obtained as a 
white viscous liquid. Water content < 0.05 wt %. 1H NMR (300 MHz, D2O/TSP): 3.59 
(t,4H), 2.97 (t, 2H), 2.94 (t, 2H), 2.36 (t, 8H), 2.18 (m, 8H), 1.35-1.52 (m, 16H), 0.92 (t, 
12H). 
[P4444][MES]: From MES buffer (48.5 mmol), this compound was obtained as a white 
solid. Water content < 0.05 wt %. 1H NMR (300 MHz, D2O/TSP): 3.63 (t, 4H), 2.99 (t, 
2H), , 2.72 (t, 2H), 2.50 (t, 4H), 2.02 (m, 8H), 1.27-1.42 (m, 16H), 0.92 (t,12H). 
[P4444][TES]: From TES buffer (45.1 mmol), this compound was obtained as a white 
solid. Water content < 0.05 wt %. 1H NMR (300 MHz, D2O/TSP): 3.31 (s, 6H), 2.81 (s, 
2H), 2.50 (m, 8H), 1.35-1.49 (m,16H), 0.92 (t, 12H). 
[P4444][Tricine]: From Tricine buffer (50.3 mmol), this comppound was obtained as a 
white solid. Water content < 0.05 wt %. 1H NMR (300 MHz, D2O/TSP): 3.34 (s, 6H), 
3.18 (s, 2H), 2.00 (m, 8H), 1.27-1.44 (m, 16H), 0.77 (t. 12H).  
[N4444][CHES]: From CHES buffer (47.2 mmol), this compound was obtained as a 
translucent viscous liquid. Water content < 0.05 wt %. 1H NMR (300 MHz, D2O/TSP): 
2.75 (m, 2H), 2.49-2.51 (m, 1H), 2.3 (m, 8H), 1.27-1.37 (m, 16H,), 0.94 (t, 12H). 
[N4444][HEPES]: From HEPES buffer (44.3 mmol), this compound was obtained as a 
yellow solid. Water content < 0.05 wt %.1H NMR (300 MHz, D2O/TSP): 3.34 (s,6H), 
3.17 (t, 8H), 2.51 (t, 2H), 2.34 (2H, t), 1.31 (quin, 8H ), 1.30 (sext,8 H) 0.94 (t,12 H). 
[N4444][MES]: From MES buffer (48.5 mmol), this compound was obtained as a white 
solid. Water content < 0.05 wt %. 1H NMR (300 MHz, D2O/TSP): 3.34 (t, 4H), 3.17 (t, 
8H); 2.51 (t, 2H,), 2.49 (t,2H,), 2.32 (t, 4H), 1.55 (quin 8H), 1.31 (sext, 8H), 0.94 (t,12H). 
[N4444][TES]: From TES buffer (45.1 mmol), this compound was obtained as a white 
solid. Water content < 0.05 wt %. 1H NMR (300 MHz, D2O/TSP): 3.34 (s,6H), 3.27 (t, 
8H), 2.86 (t, 2H), 2.51 (2H, t), 1.55 (quin, 8H ), 1.30 (sext,8 H) 0.91 (t,12 H). 
[N4444][Tricine]: From Tricine buffer (50.3 mmol), this comppound was obtained as a 
white solid. Water content < 0.05 wt %. 1H NMR (300 MHz, D2O/TSP): 3.53 (s, 6H) 3.27 
(s, 2H), 3.21 (t, 8H), 1.65 (quin, 8H), 1.37 (sext, 8H), 0.93 (t,12H). 
The chemical structures and synthetic pathways of the synthesized GB-ILs are displayed 
in Figure 9 for the [P4444][GB] ILs and in Figure 10 for the [N4444][GB] ILs. 
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Figure 9 - The synthetic pathway for [P4444][GB]. 
 
Figure 10 - The synthetic pathway for [N4444][GB]. 
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2.3.2. Phase diagrams and tie-lines (TLs) 
The phase diagrams for the systems composed of C6H5K3O7, water, and the 
[P4444][GB] and [N4444][GB] ILs are illustrated in Figure 11 and Figure 12, respectively. 
The obtained results for the diagrams of the ABS containing the [N4444][GB] ILs are in 
close agreement with literature data and are presented in Appendix D (25). The 
experimental data are shown in molality units in order to avoid differences that could 
result from different molecular weights, which allow a better understanding of the impact 
of the ILs molecular weight and structure on the phase diagrams behaviour. The detailed 
experimental data corresponding to the ternary phase diagrams are presented in Appendix 
E. For all studied ABS, the bottom phase is mostly composed of salt and water while the 
top phase corresponds to the IL-rich phase. This is an useful advantage considering the 
IL recovery, which may follow thereafter (146). In the presented phase diagrams, the 
biphasic region is located above the solubility curve. Below the solubility curve, the 
concentration of each component is not sufficient to induce liquid-liquid demixing thus 
falling within the monophasic regime. Considering the representations in Figure 11 and 
Figure 12, the closer the axis is the binodal curve, the larger the biphasic area and the 
stronger the demixing ability of the IL, i.e. the easier the IL is salted-out by the salt. 
Regarding the phosphonium-based ILs, the IL anion ability to form an ABS, for 
instance at 1.0 mol·kg-1 of C6H5K3O7, follows the order: [P4444][CHES] > [P4444][MES] 
≈ [P4444][HEPES] > [P4444][TES] ≈ [P4444][Tricine] (Figure 11). For ammonium-based 
ILs, the order keeps almost the same: [N4444][CHES] > [N4444][MES] ≈  [N4444][HEPES] 
> [N4444][TES] ≈ [N4444][Tricine] (Figure 12). The formation of an ABS depends on the 
type of salt and IL, as well as on their concentrations, temperature and other features, such 
as the pH of the medium. The salting-out effect of the salt over the IL, in aqueous media, 
strongly affects the ABS formation. The salt ions dissolved in an aqueous solution are 
surrounded by a layer of water molecules, a process known as hydration (147). When an 
salt is added to an aqueous solution of IL the two solutes will compete for the solvent 
molecules. The competition is usually won by the salt ions and, consequently, it occurs a 
migration of solvent molecules away from the ions of the IL towards those of the salt, 
which decreases the hydration and therefore the solubility of the IL in water – a process 
known as salting-out.  
Accordingly to the Hofmeister series, which provides a qualitative ranking of salt 
anions and cations based on their effectiveness as protein precipitants, C6H5K3O7 is a salt 
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with a strong salting-out capacity since it is composed of a trivalent charged anion (148). 
This organic salt anion has a strong affinity to water and thus there is an exclusion of the 
IL from the aqueous media, promoting the separation of the phase rich in IL from the rest 
of the solution. Since the set of ILs presented in Figure 11 and Figure 12 share the same 
IL cation, it is possible to evaluate the effect of the IL-anion on the ABS formation; the 
temperature (25 ºC) and pressure (1 bar) were also fixed in all experiments. Anions, when 
compared to cations, have a higher aptitude for hydration since they are more polarized 
and have a more diffuse valence electronic configuration (147). Consequently, anions 
with lower hydrogen bond basicity values present lower ability to create hydration 
complexes, being more easily salted-out by salts. No hydrogen-bond basicity values have 
been reported for GB-ILs anions. However, some conclusions can be drawn using use of 
the water-octanol partition coefficients (Kow) of each GB-IL. The higher the value of 
log(Kow) the higher is the affinity of a given anion for the octanol-rich phase. As greater 
it is the affinity of a compound for the octanol-rich phase, the lower it is its polarity. As 
a result anions with higher log(Kow) values are more easily separated into two phases and 
their phase diagrams are located near the binodal origin. The Kow value of each buffer 
strongly reflects their affinity for water molecules. The values of log(Kow) are as follow: 
CHES: -0.59; MES: -2.48; HEPES: -3.11; TES: -4.48; Tricine: -5.25 (149). Therefore, 
these values are in close agreement with the trends depicted in Figure 11 and Figure 12. 
The phase diagrams for the ILs composed of the anions with higher log(Kow) ([CHES]
-, 
[HEPES]- and [MES]-) are nearest the bimodal. On the other hand, the phase diagrams 
for the ILs composed of the anions with lower log(Kow) ([TES]
- and [Tricine]-) are those 
that are more distant from the axes origin.  
The presence of –OH groups on the ILs chemical structures also increases their 
hydrogen bonding capacity with water, which turns more difficult the salting-out process 
by the citrate-based salt. The phase diagrams of ILs composed [Tricine]- and [TES]-, 
which are anions composed of more than one –OH group, are those that are more distant 
from the axes origin. This means that these systems need more salt for two-phase 
formation. Then, [HEPES]-, with only one –OH group is followed by [MES]- and [CHES]- 
, with no –OH groups. Nevertheless, the presence of –OH groups and the ILs affinity for 
water is further reflected on the Kow values.   
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Figure 11 - Ternary phase diagrams for systems composed of IL + C6H5K3O7 + water at (25 ± 1) 
°C and atmospheric pressure in mol.kg-1: (×) [P4444][CHES], (■) [P4444][HEPES], (♦) 
[P4444][MES], (●) [P4444][TES] and (▲) [P4444][Tricine]. 
 
 
Figure 12 - Ternary phase diagrams for systems composed of IL + C6H5K3O7 + water at (25 ± 1) 
°C and atmospheric pressure in mol.kg-1: (×) [N4444][CHES], (■) [N4444][HEPES], (♦) 
[N4444][MES], (●) [N4444][TES] and (▲) [N4444][Tricine]. 
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The effect of the IL cation is presented in Figure 13. Both cations, [P4444]
+ and 
[N4444]
+, reveal a high ability to form ABS in presence of C6H5K3O7 aqueous solutions. 
However, the obtained results are not conclusive regarding the systems composed of 
[Tricine]- and [HEPES]- anions. In these systems, no meaningful differences were 
observed concerning their capability to form ABS in presence of C6H5K3O7. Although 
both types of compounds are composed of four alkyl chains with the same size, the 
[P4444]
+ ability to form the two-phase systems is higher than that displayed by [N4444]
+, for 
all the other remaining systems. It suggests that there are some contributions derived from 
the central atom at the cation core, which influence the ABS formation. Analogous results 
were reported for ABS composed of more conventional ILs such as: [P4444]Cl and 
[N4444]Cl combined with Na2CO3 and C6H5K3O7 (146,150). In general, due to their highly 
shielded charges, located mostly on the heteroatom that is surrounded by four alkyl chains 
and no aromatic character which is responsible for their low affinity for water molecules, 
both cations are known for their strong ability in ABS formation with salts. The lower the 
affinity for water and/or hydrophobic nature of the IL, discussed above, more effective is 
the IL in promoting the phase separation (146,151). 
 
Figure 13 - Evaluation of the cation nature in the ternary phase diagrams composed of IL + 
C6H5K3O7 + water at (25 ± 1) °C and atmospheric pressure in mol.kg-1 : (×) [P4444][CHES], (■) 
[P4444][HEPES], (♦) [P4444][MES], (●) [P4444][TES] and (▲) [P4444][Tricine], (×) [N4444][CHES], 
(■) [N4444][HEPES], (♦) [N4444][MES], (●) [N4444][TES] and (▲) [N4444][Tricine]. 
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The experimental binodal data for the studied systems were fitted by the empirical 
relationship described by Equation 1. The regression parameters A, B and C, which were 
estimated by the least-squares regression method, are provided in Table 3, along with 
their corresponding standard deviations (σ). Overall, good correlation coefficients were 
obtained, indicating that these fittings can be used to predict data in a given region of the 
phase diagram where no experimental results are available.  
 
Table 3 – Correlation parameters used to describe the experimental bimodal data by Equation 1, 
respective standard deviations (σ) and correlation coefficients (R2).   
GB-IL A ± σ B ± σ 10 5(C ± σ) R2 
[P4444][CHES] 126.0 ± 2.0 - 0.44 ± 0.01 13.78 ± 0.06 0.999 
[P4444][HEPES] 82.3 ± 0.6 - 0.25 ± 0.01 3.25 ± 0.08 0.999 
[P4444][MES] 97.6 ± 1.5 - 0.29 ± 0.01 4.34 ± 0.10 0.998 
[P4444][TES] 109.8 ± 22.5 - 0.23 ± 0.06 2.86 ± 0.44 0.981 
[P4444][Tricine] 94.8 ±1.9 - 0.22 ± 0.01 1.89 ± 2.95 0.999 
[N4444][CHES] 120.1 ± 4.7 - 0.36 ± 0.02 1.12 ± 0.47 0.998 
[N4444][HEPES] 67.3 ± 4.7 - 0.23 ± 0.02 1.85 ± 0.21 0.999 
[N4444][MES] 80.1 ± 8.3 - 0.25 ± 0.04 2.95 ± 0.50 0.997 
[N4444][TES] 160.7 ± 16.0 - 0.37 ± 0.03 1.25 ± 0.32 0.996 
[N4444][Tricine] 90.4 ± 1.6 - 0.21 ± 0.01 2.27 ± 0.01 0.999 
 
The experimental data for the TLs and their respective length (TLL) are reported in 
Table 4. In Appendix F are reported the TLs for each ABS combined with the respective 
phase diagrams. In general, the total composition of the system does not usually have a 
significant effect upon the slope of the TLs (152). This implies that the TLs are generally 
parallel to each other, as presented in the example shown in Figure 14, allowing the 
knowledge of the phase compositions for any given system.  
 
 
Table 4 – Data for the tie-lines (TLs) and respective tie-line lengths (TLL) at (25 ± 1) °C. Initial 
mixture compositions are represented as [Salt]M and [IL]M, whereas [Salt]Salt and [IL]Salt  
represent the composition of IL and salt at the IL-rich phase, respectively, and vice-versa. 
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Weight fraction composition / wt % 
IL [IL]IL [Salt]IL [IL]M [Salt]M [IL]Salt [Salt]Salt TLL 
[P4444][CHES] 58.4181 
53.3384 
2.9915 
3.7161 
21.5658 
21.6769 
15.7489 
13.3839 
3.7167 
10.9762 
21.9278 
16.6513 
57.8863 
44.2931 
[P4444][HEPES] 39.9933 
47.0802 
7.8974 
7.8974 
20.4424 
19.6265 
22.2288 
23.3039 
6.4838 
6.4526 
32.4838 
32.4838 
41.5868 
48.1599 
[P4444][MES] 45.4549 
41.0494 
6.4378 
8.6166 
20.0039 
19.8486 
22.5176 
21.4342 
4.8522 
7.1823 
31.7285 
29.0920 
48.6869 
39.5755 
[P4444][TES] 53.3864 
44.6798 
9.3191 
13.2572 
20.1175 
20.2998 
28.7076 
27.9458 
7.0057 
7.9131 
36.3489 
35.4086 
53.6822 
42.9241 
[P4444][Tricine] 44.8550 
42.6900 
10.7267 
11.9573 
19.9908 
20.4195 
30.0090 
28.0210 
6.7839 
13.2939 
40.2462 
33.1607 
48.1748 
36.2452 
[N4444][CHES] 68.0848 
64.8733 
2.7169 
2.8843 
19.9442 
20.4611 
24.2430 
20.7988 
0.2290 
1.3093 
33.4421 
28.5241 
72.6707 
68.5404 
[N4444][HEPES] 62.0163 
40.6380 
0.1252 
4.7148 
19.8522 
19.7431 
29.5671 
24.1009 
4.6970 
7.3500 
40.1495 
35.5992 
69.9103 
45.4085 
[N4444][MES] 52.7680 
61.8115 
2.7461 
1.0649 
20.1521 
19.8977 
24.8860 
29.7056 
4.9861 
1.7287 
35.1807 
42.1209 
57.7504 
72.7705 
[N4444][TES] 37.3675 
74.3040 
14.7886 
4.3640 
18.9075 
20.6716 
28.3520 
34.6771 
11.7925 
5.0115 
33.5797 
43.5282 
31.7362 
79.5946 
[N4444][Tricine] 68.7572 
54.8910 
1.7395 
5.6872 
30.1636 
28.0005 
29.9058 
23.3887 
0.9659 
9.3062 
51.2148 
35.6949 
83.9253 
54.5750 
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Figure 14 – Phase diagrams for the ternary systems composed of C6H5K3O7 + [P4444][CHES] + 
water at (25 ± 1) °C and atmospheric pressure: binodal data (●), TL1 data (●), TL2 data (●), 
adjusted binodal data using Equation 1 (-). 
 
2.3.3. Purification of IgY using GB-ILs + C6H5K3O7 ABS 
Initially, the extraction and purification of IgY was tested using a ternary mixture with 
a selected mixture point composed of 30 wt % of GB-IL and 30 wt % of C6H5K3O7. In 
Figure 15 it is presented the macroscopic appearance of a ternary mixture with the 
selected point. It should be highlighted that the organic salt, C6H5K3O7, was chosen to 
perform the extraction and purification experiments of IgY due to its biodegradable and 
non-toxic nature (150).  
The mixture compositions firstly used were not appropriated for the extraction and 
purification of IgY since a large amount of precipitated proteins was found - Figure 15. 
Moreover, in some situations, it was not evident the formation of ABS. The visible 
turbidity in Figure 15 suggests that some proteins present in the WSPF such as IgY, γ-, 
α- and β-livetin are being precipitated.  
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Figure 15  - ABS composed of 30 wt % [P4444][CHES] +  30 wt % C6H5K3O7 +  WSPF. 
 
After these experiments, a fixed tie-line length (TLL) of ≈ (40 ± 5) was tested while 
decreasing the IL composition to 20 wt % in all the experiments, with the exception of 
the system composed of GB-IL [N4444][Tricine] since at this composition a monophasic 
systems will be formed. For this IL, the mixture point evaluated was 25 wt % 
[P4444][Tricine] +  30 wt % C6H5K3O7. The main goal was to reduce the concentrations 
of the phase-forming components to avoid the protein’s precipitation while still assuring 
the formation of ABS. The implementation of a fixed TLL also allows avoiding 
differences in the compositions of the coexisting phases amongst the ten IL-based ABS 
studied. In Figure 16 and Figure 17 it is presented the macroscopic appearance of the 
ternary mixtures with the compositions described in Table 5. By visual inspection, it was 
possible to observe a significant amount of precipitated protein in the systems composed 
of [P4444][HEPES], [N4444][HEPES] and [N4444][TES]. 
 
     
Figure 16 – ABS formed by [P4444][GB] + C6H5K3O7 + WSPF: (A) 21.6 wt % [P4444][CHES] + 
13.4 wt % C6H5K3O7, (B) 20.4 wt % [P4444][HEPES] + 22.2 wt % C6H5K3O7, (C) 19.8 wt % 
[P4444][MES] + 21.4 wt % C6H5K3O7, (D) 20.3 wt % [P4444][TES] + 27.9 wt % C6H5K3O7, (E) 
20.0 wt % [P4444][Tricine] + 29.0 wt % C6H5K3O7. 
 
(A) (B) (C) (D) (E) 
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Figure 17 - ABS formed by [N4444][GB] + C6H5K3O7 + WSPF: (A) 20.1 wt % [N4444][CHES] + 
16.9 wt % C6H5K3O7, (B) 20.0 wt % [N4444][HEPES] + 22.9 wt % C6H5K3O7, (C) 20.2 wt % 
[N4444][MES] + 21.9 wt % C6H5K3O7, (D) 20.1 wt % [N4444][TES] + 28.2 wt % C6H5K3O7, (E) 
24.8 wt % [N4444][Tricine] + 30.1 wt % C6H5K3O7. 
 
Table 5 – Mixture composition for the ABS composed of GB-ILs and salt for the purification of 
IgY from the WSPF and respective TLL. 
ABS [GB-IL] / (wt %) [C6H5K3O7] / (wt %) [WSPF] / (wt %) (≈) TLL  
[P4444][CHES] 21.6 13.4 65.0 44.3 
[P4444][HEPES] 20.4 22.2 57.4 41.6 
[P4444][MES] 19.8 21.4 58.8 39.6 
[P4444][TES] 20.3 27.9 51.8 42.9 
[P4444][Tricine] 20.0 29.0 51.0 41.6 
[N4444][CHES] 20.1 16.9 63.0 39.1 
[N4444][HEPES] 20.0 22.9 57.1 42.3 
[N4444][MES] 20.2 21.9 57.9 40.5 
[N4444][TES] 20.1 28.2 51.7 43.9 
[N4444][Tricine] 24.8 30.1 45.1 69.8 
 
In all the studied systems no proteins were detected at the salt-rich phase, which is 
supported by the results presented in the HPLC chromatograms, as well as in the SDS-
PAGE gels, both discussed below. This occurrence can be a direct result of the strong 
salting-out ability of C6H5K3O7, which leads to the exclusion of all the proteins of the 
WSPF from the salt-rich phase to the IL-rich phase. Even though the C6H5K3O7 –rich 
phase is more hydrated, comparatively to the GB-IL-rich phase, proteins revealed a higher 
affinity for the GB-IL-aqueous phases. As mentioned, the interaction of the proteins with 
(E) (B) (C) (D) (A) 
50 
 
 
the IL phase-forming components seems to be quite complex phenomenon and as will be 
discussed below. Particularly, the partitioning in ABS is a process whereby the exposed 
groups of the proteins come into contact with the phase components, being therefore a 
surface-dependent phenomenon (153). It is known that a protein interacts with the 
surrounding molecules within a phase through different kinds of interactions namely 
hydrogen-bonding, electrostatic interactions, π···π interactions between the aromatic 
groups and dispersive-type interactions between the aliphatic groups. The effect of these 
interactions is expected to be different in the two phases and the proteins will partition 
preferentially into one phase, being, in that specific case, the IL-rich phase 
Good’s buffers are zwitterionic amino acids, either N-substituted taurine or glycine 
derivatives, with two protonation sites namely at the carboxylic/sulfonic group (pKa1) and 
at the amino group (pKa2) (139). These are responsible for their buffering ability near the 
physiological pH region. All the extractions performed in this work were carried out in a 
buffered alkaline medium. The pH values of both phases in each ABS are presented in 
Table 6. The GB-ILs used in the current work were already used as anions in the 
development of ILs that allowed the control of the pH, hence acting as protein stabilizers, 
namely BSA (25). Though the GB-IL-based systems studied allowed to maintain the pH 
values of each phase within 7.8 - 10.9, some precipitation and/or denaturation was 
observed in some systems, namely in those composed of [P4444][HEPES], 
[N4444][HEPES] and [N4444][TES].    
 
Table 6 – pH values of the coexisting phases of the ABS composed of GB-ILs + C6H5K3O7. 
IL pH (IL-rich phase) pH (salt-rich phase) 
[P4444][CHES] 10.8 10.4 
[P4444][HEPES] 9.2 9.1 
[P4444][MES] 8.0 7.8 
[P4444][TES] 8.8 8.4 
[P4444][Tricine] 10.2 10.2 
[N4444][CHES] 10.9 10.5 
[N4444][HEPES] 9.9 9.5 
[N4444][MES] 7.9 7.7 
[N4444][TES] 9.4 9.2 
[N4444][Tricine] 9.9 9.5 
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The SDS-PAGE of the ten GB-IL-based systems was also carried out to identify the 
major proteins in the WSPF and to determine the IgY amount in the IL-rich phase, after 
the extraction. The protein profiles obtained from the WSPF, as well as of the coexisting 
phases of the ABS composed of [P4444][GB] or [N4444][GB] + C6H5K3O7 + WSPF are 
presented in Figure 18 and Figure 19, respectively.  
The commercial pure IgY, under reducing conditions, presents two major bands at 65 
kDa and 25 kDa which correspond to the two heavy chains and the two light chains, 
respectively. The SDS-PAGE of the salt-rich phase, i.e., the bottom phase samples, did 
not show any bands. Therefore, there systems seem to be good alternatives for extraction 
but they do not allow any purification since no selective extractions were attained. In the 
SDS-PAGE of the IL-rich phases of the systems composed of [P4444][HEPES], 
[P4444][Tricine], [N4444][HEPES] and [N4444][TES], in addition to the β–livetin fraction, 
only a band around 65 kDa is detectable. It should be noted that, by a visual inspection of 
the ABS, three of the stated systems shown a significant amount of precipitated protein, 
namely those composed of [P4444][HEPES], [N4444][HEPES] and [N4444][TES]. However, 
as the visible precipitate may correspond to other contaminant proteins rather than the 
IgY, the SDS-PAGE of both phases of these systems was also carried out. The SDS-
PAGE analysis of the precipitate was further attempted. However, due to problems 
regarding the precipitate solubilization this step was not successfully accomplished.  
 The light chain band of IgY allows a better and unambiguous evaluation of the 
presence of IgY, due to the fact that the heavy chain band can induce some error since it 
has a similar molecular weight to the other unidentified contaminant proteins present in 
the WSPF, which also appear around 65 kDa. Taking this phenomenon into account, the 
light chain band was used to determine the amount of IgY at the IL-rich phase through 
the establishment of a previous calibration curve. The quantification results are presented 
in Table 7. The gels used for the IgY quantification and the respective calibration curve 
are reported in Appendix C, in Figure C. 1 and Figure C. 2, respectively. Overall, the 
ABS composed of the [N4444][GB] ILs provided the best results, providing extraction 
yields in the range of 31.18 to 37.18 %. Among those, the ABS that allowed the extraction 
of a higher amount of IgY (7.38 g/L), also combined with the best yield (37.18 %), was 
the ABS featuring the [CHES]- anion. As demonstrated above, among all the [N4444][GB] 
ILs studied, the IL [N4444][CHES] is the most hydrophobic. This inherent hydrophobicity 
rises the opportunity for dispersive-type interactions of the proteins present in the water 
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soluble fraction with these more hydrophobic ILs. For the ABS composed of 
[P4444][HEPES], [P4444][Tricine], [N4444][HEPES] and [N4444][TES] the quantification 
was not accomplished. The SDS-PAGE gels of the stated ABS did not show any band 
corresponding to the IgY light chain band, as depict in Figure 18 and Figure 19. This is 
thought to be the result of IgY precipitation. 
 
 
Figure 18 - SDS-PAGE of a gel loaded with samples of bottom and top phases from systems 
composed of [P4444][GB] + C6H5K3O7 stained with Coomassie blue: 
Lane 1 (Std): Standard molecular weights. 
Lane 2 (Pure IgY): Pure IgY, purified using the commercial kit EggsPure IgY.   
Lane 3 (A): WSPF. 
Lane 4 (B): Bottom and top phases, respectively, of the ABS composed of 21.6 wt % 
[P4444][CHES]  13.4 wt % C6H5K3O7. 
Lane 5 (C): Bottom and top phases, respectively, of the ABS composed of 20.4 wt % 
[P4444][HEPES] + 22.2 wt % C6H5K3O7. 
Lane 6 (D): Bottom and top phases, respectively, of the ABS composed of 19.8 wt % [P4444][MES] 
+ 21.4 wt % C6H5K3O7. 
Lane 7 (E): Bottom and top phases, respectively, of the ABS composed of 20.3 wt % [P4444][TES] 
+ 27.9 wt % C6H5K3O7. 
Lane 8 (F): Bottom and top phases, respectively, of the ABS composed of 20.0 wt % 
[P4444][Tricine] + 29.0 wt % C6H5K3O7. 
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Figure 19 – SDS-PAGE of a gel loaded with samples of bottom and top phases from systems 
composed of [N4444][GB] +  C6H5K3O7 stained with Coomassie blue: 
Lane 1 (Std): Standard molecular weights. 
Lane 2 (Pure IgY): Pure IgY, purified using the commercial kit EggsPure IgY.   
Lane 3 (A): WSPF. 
Lane 4 (B): Bottom and top phases, respectively, of the ABS composed of 20.1 wt % 
[N4444][CHES] + 16.9 wt % C6H5K3O7. 
Lane 5 (C): Bottom and top phases, respectively, of the ABS composed of 20.0 wt % 
[N4444][HEPES] + 22.9 wt % C6H5K3O7. 
Lane 6 (D): Bottom and top phases, respectively, of the ABS composed of 20.2 wt % 
[N4444][MES] + 21.9 wt % C6H5K3O7. 
Lane 7 (E): Bottom and top phases, respectively, of the ABS composed of 20.1 wt % [N4444][TES] 
+ 28.2 wt % C6H5K3O7. 
Lane 8 (F): Bottom and top phases, respectively, of the ABS composed of 24.8 wt % 
[N4444][Tricine] + 30.1 wt % C6H5K3O7. 
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Table 7 – Concentration and recovery yield of IgY in the IL-rich phase. 
GB-IL [IgY] / (g/L) Yield (%) 
[P4444][CHES] 4.45 12.44 
[P4444][MES] 0.14 13.71 
[P4444][TES] 0.19 16.10 
[N4444][CHES] 7.38 37.18 
[N4444][MES] 4.46 31.18 
[N4444][Tricine] 2.84 31.35 
 
The results obtained by HPLC were similar in all the studied systems. Figure 20 
depicts the HPLC chromatograms of the top and bottom phases of the ABS composed of 
[N4444][Tricine] + C6H5K3O7 + WSPF. The chromatograms corresponding to all the 
extractions carried out in this work are presented in Appendix G in Table G. 1  and Table 
G. 2, for the [P4444][GB] ILs and [N4444][GB] ILs, respectively.  The HPLC allowed the 
separation of some proteins which are originally present in the WSPF: IgY, with 15 min 
of retention time, and other non-identified contaminant proteins (17-18 min). As 
mentioned, no proteins were found in the chromatograms corresponding to the bottom 
phases, agreeing with the results discussed before and attained by SDS-PAGE. Regarding 
the top phase samples, it was expected the presence of a peak at 15 min of retention time, 
corresponding to IgY. Instead, it was detected a new peak, at a lower retention time (12 
min), which is thought to be an IL-protein complex resulting from the high interaction of 
each IL with IgY. The peaks after 20 min belong mostly to the IL and salt present in the 
system, as confirmed by the HPLC chromatograms of the IL-based ABS for which no 
IgY or WSPF was added. 
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Figure 20 – SE-HPLC chromatogram of a system composed of 24.8 wt % [N4444][Tricine] + 
30.1 wt % C6H5K3O7 + 45.1 wt % WSPF: bottom phase ( ̶ ), top phase ( ̶ ) and initial WSPF ( ̶ ). 
 
 
Aiming the confirmation of the phenomenon that occurs between the IgY and the ILs, 
an additional SE-HPLC study was performed using mixtures composed of pure IgY + 
GB-ILs or salt. In Figure 21 and Figure 22 are presented the  chromatograms 
corresponding to the pure IgY sample, as well as the chromatograms of mixtures 
composed of pure IgY plus 40.0 wt % [N4444][CHES] and 8.1 wt % C6H5K3O7 . By the 
inspection of these chromatograms it is possible to conclude that the IL interferes with 
the IgY in aqueous solution, while the salt has no significant effect under its retention 
time. Similar results were obtained for all GB-ILs. Several studies were then developed 
in order to understand this particular type of interaction. In addition, some techniques 
were further tested aiming the recovery of the proteins from the WSPF of egg yolk, from 
the IL-rich phase. These studies are reported and discussed in Chapter 3. 
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Figure 21 - SE-HPLC chromatogram of the pure IgY solution ( ̶ ) and of a mixture composed of 
[N4444][CHES] + pure IgY ( ̶ ) 
 
Figure 22 - SE-HPLC chromatogram of the pure IgY solution ( ̶ ) and of a mixture composed of 
C6H5K3O7 + pure IgY( ̶ ) 
 
A molecular docking study was then performed in order to further investigate the 
binding sites of the ILs [P4444][GB] and [N4444][GB] ions with IgY, aiming to obtain more 
information regarding the affinity and stability of IgY in the IL-rich aqueous phases. 
Molecular docking is a computational procedure that allows to predict noncovalent 
binding of macromolecules, such as proteins, with the aim of predicting the bond 
conformations and the binding affinity (144). The crystal structure of the fragment 
crystallisable region of IgY i.e., the Fc region or tail, was used to identify the hydrogen-
bonding interaction and binding sites between the IL ions and the protein. The interaction 
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sites of IgY with the [P4444]
+ and [N4444]
+ cations were identified and the hydrogen-
bonding results are displayed in Figure 23 (144). Binding free energies of -4.0 kcal mol-
1 were obtained for both cations. The residues found next to the [P4444]
+ cation  are Arg485, 
Glu551, Asn449, Trp423,Ser445, Pro484, Pro359, Arg448, Tyr447, Asp486, Pro356, 
Thr450, and Val446 (Figure 24 (B)), and those found nearby [N4444]
+ are: Arg485, 
Pro484, Pro357, Val446, Thr450, Arg448, Pro359, Glu551, Pro356, Ser445, Asn449, 
Asp486, Leu362, Trp423, Tyr447, and Gly451) (Figure 24 (C)). The similarities obtained 
from these results suggest that both IL cations establish similar interaction with IgY – an 
expected result since both cations are similar with a central atom and four butyl chains. 
Taha et. al (139) already studied the interaction of IgY with some of the anions used in 
the current work namely [MES]-, [TES]-, [Tricine]- and [HEPES]-. They have found that 
the binding free energies of the anions [MES]-, [TES]-, [Tricine]- and [HEPES]- with IgY 
are -4.1, -4.4, 4.4 and -4.1 kcal mol-1, respectively. The residues located next to [MES]-, 
[TES]- and [Tricine]- are Gln563, Gln565, Thr561, His464, Pro460 and Ala462. On the 
other hand, [HEPES]- is located next to Asn449, Tyr447 and Arg485. The molecular 
docking results of the IL anions are displayed in Figure 24. Through these results it is 
demonstrated that the partitioning of IgY is dominated by hydrogen-bonding and van der 
Waals interactions (139). However, the GB anions [Tricine]-, [TES]-, [MES]-, and 
[HEPES]-, respectively form 9, 5, 5 and 4 hydrogen bonds with Gln565 and Gln563, while 
no information is available for [CHES]-, which was the anion that promoted  the best 
extraction results (lower losses of IgY) with both cations.  
The ABS composed of the ILs with the anion [HEPES]-, which is the one that is 
located near to the different residues of IgY and it is the anion that forms the lowest 
number of hydrogen bonds, did not allow the IgY extraction, when combined with any of 
the cations. The computational results regarding the other anions, namely [Tricine]-, 
[TES]- and [MES]-, which interact with the IgY molecule in the same residues, did not 
allow a full understanding of the partitioning behaviour. Different cations, combined with 
the same anions, promoted different results. It is important to highlight that the top phase 
of the system also has a small amount of C6H5K3O7 in its composition, which is a salt 
with a strong salting-out capacity, and therefore also strongly influences the partitioning 
behaviour of IgY. In summary, the partitioning phenomenon of IgY in the studied ABS 
is not fully understood. Though, it is possible to assure that the ILs used in the ABS 
composition are not suitable for IgY extraction.       
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Figure 23 – Molecular docking of IgY with IL cations (A): (B) [P4444]+, (C) [N4444]+. 
 
Figure 24 - Molecular docking of IgY-Fc with the IL anions; (A) [MES]-, (A) [TES]-, (C) 
[Tricine] -, (D) [HEPES]- (139).  
 
An additional study was performed in order to evaluate the proteins structure in the 
WSPF and further extraction by FT-IR (Fourier transform-infrared spectroscopy). The 
FT-IR spectra are selective in what concerns the absorption band frequency positions, 
widths and intensities in response to proteins structural changes, providing thus 
(A) (B) 
(C) (D) 
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information for identifying the structure of proteins based on energy absorption bands of 
specific functional groups or chemical bonds (154–156). The most distinct FT-IR bands 
for proteins are the amide I bonds signature, ranging from 1700 to 1600 cm-1 and thus, in 
this work, the FT-IR spectra  were obtained in that wavelength range (154,157). The 
primary components of the amide I band are mainly generated by C=O stretching 
vibrations, the band is influenced by hydrogen-bonding, and thus, information about 
conformational changes are provided (157,158). The secondary structure elements were 
resolved using a second-derivative procedure (158,159). To reveal differences in the 
proportions of the secondary structure of proteins the total area of all peaks from each 
spectrum was defined to be 100 % and the individual peak areas were expressed as 
proportions (%) of the corresponding secondary structure elements. Table 8 presents the 
assignment of the principal amide I frequencies to the protein secondary structure as 
previously described in the literature (156).  
 
Table 8 – Frequencies (cm-1) and assignments of IR bands of Amide I component frequencies to 
Protein Secondary Structure in H2O (According to second derivatives) (156). 
Wavenumber (cm-1) Assignment 
1680-1696 β–turn 
1655-1675  
1650-1657 α–helix 
1640-1651 Random coil 
1626-1640 Parallel β-sheet 
1612-1642 
1670-1690 
Antiparallel β–sheet 
     (weak) 
 
In Table 9 and Table 10 are presented the proportions of each secondary structure 
elements for the samples of the initial WSPF and the coexisting phases of the systems 
composed of [P4444][GB] + C6H5K3O7 + WSPF and [N4444][GB] + C6H5K3O7 + WSPF, 
respectively. In all the studied samples, it is possible to notice major alterations regarding 
the proportions (%) of the secondary structure elements after the extraction, which 
suggests alterations in the proteins secondary structure or protein aggregation. In general, 
it is observed an increase in the random coil and α–helix proportions, when comparing 
the top phase of the ABS samples with the initial WSPF. As is known, the secondary 
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structure of a peptide defines the spatial orientation of its backbone and the presence of 
specific hydrogen bonds (156). Thus, the systems composed of [P4444][CHES] and 
[N4444][CHES], corresponding to the more hydrophobic IL-rich phases, contribute to a 
better maintenance of the protein secondary structure, while reducing the hydrogen bonds 
between the proteins and the IL. In contrast, systems composed of more hydrophilic GB-
ILs, such as [P4444][Tricine] and [N4444][Tricine] revealed more significant changes 
regarding the proteins secondary structure. Their hydrophilicity will increase their 
hydrogen-bonding with the H2O molecules in solution, which will dehydrate the WSPF 
proteins, leading to their denaturation. These results are in close agreement with the 
literature data since it was found that proteins, such as enzymes, are more stable in more 
hydrophobic ILs than in more hydrophilic ILs (160). Also, these results agree with the 
ones discussed before regarding the protein precipitation and with the ones attained by 
SDS-PAGE. The ABS featuring the most hydrophobic ILs ([P4444][CHES] and 
[N4444][CHES]) were the ones that allowed the best extraction results, promoting less IgY 
losses by precipitation.  
Concerning the β–turn, it is possible to observe an increase in its proportions in 
systems composed of more hydrophilic GB-ILs. Even though many factors remain 
unanswered about what factors determine the β–turn formation, it is known that this 
secondary structure element is prevalent in globular proteins, and may also be possible 
sites for nucleation in protein folding (161). Its increase in the most hydrophilic systems 
may be a result of a higher protein folding, due to a decrease in proteins solubilisation. 
On the other hand, α–helix is a favoured structure in nonpolar solvents. Nevertheless, its 
proportions does not differ greatly between the different studied ABS. There is however, 
a major increase in the α–helix proportions between the WSPF and the ABS top phase 
samples. This is probably due to the fact that, in the WSPF, the proteins are in a more 
hydrated medium when compared with the IL-rich phase of the systems. In proteins or 
protein complexes, β–sheet are stabilized by hydrogen bonds between protein chains, 
oriented either in a parallel or in an antiparallel fashion (156). Once again, as expected, 
there narrowest differences in this element proportions are seen in the systems composed 
of more hydrophobic GB-ILs. In the ABS composed of more hydrophobic ILs, the 
hydrogen bond is not favoured. Instead, more hydrophilic systems present, in general, a 
major reduction the β–sheet proportions. 
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Table 9 – Proportions (%) of the secondary structure elements of the WSPF and from the top 
phase of the ABS composed of [P4444][GB] + C6H5K3O7 + WSPF. 
Amide I components (%) 
 WSPF [P4444][CHES] [P4444][HEPES] [P4444][MES] [P4444][TES] [P4444][Tricine] 
β-turn 28.27 29.46 20.36 33.99 26.02 36.59 
α-helix 7.00 12.74 13.26 13.55 11.85 14.16 
Random coil 17.38 38.82 40.25 27.43 22.17 40.69 
Parallel β-sheet 27.98 27.30 26.16 31.91 34.82 29.73 
Antiparallel β-sheet 43.63 43.34 41.92 38.23 46.50 32.77 
 
Table 10 - Proportions (%) of the secondary structure elements of the WSPF and from the top 
phase of the ABS composed of [N4444][GB] + C6H5K3O7 + WSPF. 
 Amide I components (%) 
  WSPF [N4444][CHES]  [N4444][HEPES]  [N4444][MES] [N4444][TES]  [N4444][Tricine]  
β-turn 28.27 28.54 30.41 27.76 34.24 39.63 
α-helix 7.00 10.26 13.26 13.18 13.19 12.82 
Random coil 17.38 31.91 40.25 40.96 39.07 25.08 
Parallel β-sheet 27.98 20.40 20.62 22.10 18.47 22.99 
Antiparallel β-sheet 43.63 45.70 41.92 44.77 36.89 24.57 
 
In Figure 25 and Figure 26 are depicted the FT-IR experimental data spectrum, plus 
the spectrum after deconvolution of the top phase belonging to the ABS composed of 
[N4444][CHES] + C6H5K3O7 + WSPF, and the second derivative FT-IR spectrum of the 
same sample, respectively. Regarding the peaks shifts and the secondary structure 
elements proportions, presented and discussed above, no significant variations are seen 
in the β – turn wavelength range, between the WSPF and the top phase samples. However, 
after the extraction, perturbations in the secondary structure occurred, resulting in 
changes in the α–helix proportion changes and in a peak dislocation. The WSPF sample 
exhibited an amide I band maximum at 1650 cm-1, while the sample from the top phase 
of the ABS showed an absorbance maximum at 1656 cm-1. Regarding the other secondary 
structure elements, no major changes were observed.  
In the Appendix H are depicted all the spectra obtained for the ABS composed of 
[P4444][GB] and [N4444][GB], in Figure H. 1 and Figure H. 2, respectively. In Table H. 1 
and Table H. 2 it is presented an overall comparison of the second derivative peak values 
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obtained in this work, together with the data found in the literature (157,158,162). Since 
no consistency was found between different authors (155–159,162), we selected three 
papers taking into account the similarity in the experimental conditions (157,158,162). 
Generally, major alterations were seen regarding the α–helix wavenumber range in all 
systems. The ABS top phases featuring [P4444][HEPES] and [N4444][HEPES] in their 
composition revealed major changes in the β–turn and β–sheet peaks shifts. These 
significant alterations, in terms of the secondary structure peak shifts, indicate significant 
changes regarding the WSPF proteins stability after the extraction. The results obtained 
for these two systems are in close agreement with the SDS-PAGE electrophoresis results, 
since no quantification was accomplished, which may be due to the significant changes 
regarding the proteins secondary structure.  
The obtained results corroborate the possible formation of protein aggregates after 
being extracted into the IL-rich phase. However, the systems composed of [P4444][CHES] 
and [N4444][CHES], which have more hydrophobic IL-rich phases, reveal to contribute to 
a better maintenance of the protein secondary structures. These results are in close 
agreement with the literature data, where proteins are more stable in more hydrophobic 
ILs than in hydrophilic ones (163,164). Still, no conclusive and insightful differences 
were observed between the systems that provided the best extraction results when 
compared with others, which did not allow the IgY extraction. It is important to bring up 
that there are some complications which indicate that there is no simple correlation 
between the IR spectra and the secondary structural components (158). Some minor 
structures can interfere with the band assignments indicated above, such as the β–turn 
band at approximately 1665 cm-1 is near the characteristic IR band representing the 310-
helices, vibrations of some amino acid side chains might make small contributions to the 
intensity of characteristic protein amide bands and, in addition, the experimental 
procedure might also bring some errors. 
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Figure 25 - FT-IR experimental data spectra of a top phase sample of an ABS composed of 20.1 
wt % [N4444][CHES] + 16.9 wt % C6H5K3O7 + 63.0 wt % WSPF (  ̶  ) and the resultant 
deconvolution spectra ( ).  
 
 
Figure 26 – FT-IR spectra of a top phase sample of an ABS composed of 20.1 wt % 
[N4444][CHES] + 16.9 wt % C6K3H5O7 + 63.0 wt % WSPF (  ̶  ) and WSPF ( - ∙ - ). 
 
2.4 – Conclusions 
In this work it was evaluated the capacity of GB-IL-based ABS, combined with the 
biodegradable salt C6H5K3O7, for the extraction and purification of antibodies from the 
WSPF of egg yolk. In this chapter, the synthesis and characterization of the GB-ILs was 
described, together with the determination of the phase diagrams for each ABS, and the 
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respective TLs and TLLs. The diversity of GB-ILs investigated allowed to study the 
influence of the IL cation and anion on the ABS formation. Overall, an increase in the 
hydrophobicity of the IL promotes the ABS formation, following the same behaviour of 
other more conventional ILs and salts ABS. According to the results obtained, the ability 
of the studied systems to form ABS follows the trend: [P4444][CHES] > [P4444][MES] ≈ 
[P4444][HEPES] > [P4444][TES] ≈ [P4444][Tricine], for the phosphonium-based ILs and 
[N4444][CHES] > [N4444][MES] ≈  [N4444][HEPES] > [N4444][TES] ≈ [N4444][Tricine], for 
ammonium-based ILs.  
The extraction and purification of the IgY with the investigated systems was not 
successfully achieved. Despite the already proved efficiency of  GB-ILs in the separation 
and extraction of proteins, which are sensitive to the pH of the medium, the studied ABS 
probably induced the formation of an IL-IgY complex or induced the precipitation of the 
proteins of the WSPF of egg yolk, as a result of the diverse type of interactions of the 
proteins of the water soluble fraction of egg yolk with cations of long alkyl side chains. 
This fact made it impossible to perform an efficient extraction and purification of IgY 
from the other proteins from the WSPF. However, the ABS composed of 20.1 wt % 
[N4444][CHES] + 16.9 wt % C6H5K3O7 provided the best results, being the most promising 
amongst the ten studied ABS. Regarding the IgY quantification, obtained through the 
analysis of the intensity of the bands from the SDS-PAGE stained gels, this system 
allowed the extraction of 7.38 g/L of IgY and a recovery yield of 37.18 %, which 
represents the best yield value among all the studied ABS. When compared with the other 
systems, this ABS also provided a greater protein stability as confirmed by the study of 
the secondary structure elements proportion analysis and the second derivative FT-IR 
spectrum peaks.  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3. Recovery of the proteins in the IL-rich 
phase for further analysis 
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3.1 - Introduction 
Taking into account the possible precipitation of IgY, when using the investigated 
ABS, and as evidenced by the vanishing of the IgY peak from the HPLC chromatograms, 
after a careful phases separation, some techniques were applied in order to recover the 
proteins from the IL-rich phase of the ABS.  
Protein precipitation is commonly accomplished by altering the solvent conditions 
and taking advantage of the changes in solubility of the protein of interest relative to those 
of many of the other components in solution (165). Different protein precipitation 
techniques (by the addition of organic solvents, acids and salts) act through different 
modes (166). In general, the proteins three-dimensional structure is maintained through 
some interactions such as hydrogen bonds, hydrophobic and ionic interactions (160). 
Protein’s solubility is the result of polar interactions with the aqueous solvent, ionic 
interactions with the salts and repulsive electrostatic forces between like charged 
molecules (166,167). Taking this into account, a small change in the microenvironment 
of proteins can disrupt these interactions, causing their denaturation which leads to 
protein unfolding and inactivation (160).  
As referred, precipitants exert specific effects on proteins (166). Organic solvent 
precipitants, such as acetone, methanol and ethanol, lower the dielectric constant of a 
protein solution, increasing the attraction between charged molecules which facilitates 
electrostatic protein interactions (166,167). Additionally, through their polar groups, 
these solvents interact with polar groups on the proteins, in competition with water (167). 
Thus, the hydrophobic interactions between proteins are minimized and electrostatic 
interactions become predominant, leading to protein aggregation (166,168). Acidic 
reagents form insoluble salts with the positively charged amino groups of the protein 
molecules at pH values below their pI. Proteins are precipitated as the salt ions become 
hydrated and the available water molecules decrease, drawing the water away from the 
protein hydrophobic surface regions which results in aggregation of protein molecules 
via protein-protein hydrophobic interactions (166).  
Dialysis and ultrafiltration exploit equivalent separation mechanisms, since both 
techniques employ a semipermeable barrier or membrane to separate the sample 
containing the desire solute, from a sample-free solution (168). Dialysis, which is the 
most popular method employed for removal of low-molecular-weight solutes from large 
protein molecules, is a size-based separation of molecules by selective diffusion through 
68 
 
 
a semipermeable membrane (168). This technique has the advantage of allowing the 
buffer exchange under benign or physiological conditions with minimum risk of 
impacting the target protein. The dialysis membrane usually possesses a specific pore size 
(molecular weight cut-off) which permits the free passage of molecules smaller than this 
in both directions. On the other hand, ultrafiltration is a pressure driving membrane-based 
process (169). Ultrafiltration membranes can operate at a wide temperature range, from 
2 to 26 ºC, which are mechanically stronger than those used in dialysis, since 
ultrafiltration works by conventional mass transfer driven by pressure differences applied 
across the membrane (168).  
In this work, two different protein precipitation techniques, acetone and 
trichloroacetic acid (TCA) precipitation, plus ultrafiltration and dialysis, were tested. 
These protocols were developed in order to isolate the IgY from the IL and the other top 
phase components. These compounds are present in the IL-rich aqueous phase and are 
responsible for the suspected target protein agglomeration and/or denaturation. 
 
3.2 – Experimental section 
3.2.1 – Chemicals 
Acetone (C3H6O, 100 % purity) was obtained from VWR Normapur. Analytical TCA 
was aquire from Prolabo. Sodium dodecylsufate (SDS, 99 % purity) was purchased from 
Alfa Aesar.  
 
3.3 – Experimental procedure 
3.3.1 – Acetone precipitation 
After a careful separation of the phases of the ABS, an acetone precipitation procedure 
was applied to all samples. First, 400 µL of acetone, previously stored at -20 ºC, was 
added to 100 µL of each sample. The mixture was then incubated for 1 h, at -20 ºC. After 
the incubation, the mixture was centrifuged at 14 000 g, at 4 ºC, for 30 min. The 
supernatant was gently discarded and the acetone excess was evaporated at room 
temperature (25 ± 1) °C. The resultant pellet was solubilized in a 100 mM phosphate 
buffer + NaCl 0.3 M, pH 7.00 and its protein profile was investigated by SE-HPLC. 
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3.3.2 – Trichloroacetic acid (TCA) precipitation 
For the TCA precipitation method, two solutions were initially prepared: a 100 % 
(w:v) TCA solution (solution 1), by dissolving 2.2 g of TCA in 1 mL of H2O, and a 10 % 
(v/v) solution (solution 2) by adding 0.1 mL of 100 % (w:v) TCA solution to 0.9 mL of 
H2O. These solutions were kept in ice cold. After, 0.11 volumes of solution 1 were added 
to the protein sample and the mixture was stored for 10 min, at -20 ºC. After, 500 µL of 
the ice-cold solution 2 were added to the sample and it was incubated at -20 ºC, for 30 
min. The supernatant was carefully removed, the pellet was washed with 500 µL of 
acetone and left to dry at room temperature. The resulting pellet was ressuspended in a 
100 mM phosphate buffer + NaCl 0.3 M, pH 7.00 and it protein profile was studied by 
SE-HPLC. 
 
3.3.3 – Dialysis  
A dialysis procedure was tested with the IL-rich phase of each ABS, after the partition 
experiments. Initially, 200 µL of each IL-rich phase sample were added inside a dialysis 
cellulose membrane, acquired from Sigma-Aldrich, with a molecular weight cut-off of 
14.0 kDa. A 100 mM phosphate buffer + NaCl 0.3 M, pH 7.00 (dialysate) was added on 
the opposite side of the membrane. The experiment was performed during 3h, at room 
temperature (≈ 25 ± 1) °C and the dialysate was replaced in every 1h. The same procedure 
was developed using a 4 % (w:v) and 6 % (w:v) SDS solution within the dialysis 
membrane. 
 
3.3.4 – Ultrafiltration 
The ultrafiltration protocol was applied in samples of both bottom and top phases of 
each ABS. In order to carry out the ultrafiltration procedure, Amicon Ultra-0.5 mL 
centrifugal Filters, from Merck Millipore, were used. Each device is supplied with two 
microcentrifuge tubes. During the experiment, one tube is used to collect the filtrate and 
the other one is used to recover the precipitated sample (Figure 27). First, 200 µL of each 
sample were added to the Amicon Ultra-0.5 mL device and then centrifuged at 14 000 g, 
for 10 min, at room temperature (≈ 25 ± 1) °C. The precipitated sample was solubilized 
in 200 µL of a 100 mM phosphate buffer + NaCl 0.3 M, pH 7.00.  
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Figure 27 – Schematic representation of the ultrafiltration procedure. 
 
The described protocol was also executed using a 1 % (w:v) and 10 % (w:v) SDS 
solutions (aiming at increasing the proteins solubility). After a first ultrafiltration step, 
similar to the one described above, the pellet was washed with a 1 % (v:v) SDS solution 
and centrifuged at 14 000 g, for 10 min, at room temperature (≈ 25 ± 1) °C. The pellet 
was then washed with a 10 % (w:v) SDS solution and centrifuged at 14 000 g, for 10 min, 
at (≈ 25 ± 1) °C. The precipitated sample was solubilized in 200 µL of a 100 mM 
phosphate buffer + NaCl 0.3 M pH 7.00, and its protein profile was investigated by SE-
HPLC. 
 
3.4. Results and discussion  
The acetone precipitation procedure was applied in samples of each phase, of each 
ABS. The results obtained from these experiments were not satisfactory due to the 
inability of dissolving the resultant pellet in the 100 mM phosphate buffer + NaCl 0.3 M, 
pH 7.00 solution, impeding the study of its protein profile by HPLC.  
The TCA precipitation procedure was then tested using a WSPF sample. The HPLC 
chromatogram obtained is displayed in Figure 28. The obtained pellet was successfully 
resuspended in the 100 mM phosphate buffer + NaCl 0.3 M, pH 7, allowing its protein 
profile analysis by HPLC. By the analysis of the chromatogram, it is possible to confirm 
the occurrence of some protein loss or denaturation, and in particular for IgY, that is 
completely lost and does not appear.  
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Figure 28 – Chromatogram of an original WSPF sample ( ̶ ) and a sample of the WSPF after 
being exposed to the TCA precipitation procedure ( ̶ ).  
 
After, and with the aim of preserving the IgY molecule in the interior of the dialysis 
cellulose membrane, while allowing the repulsion of the IL for the exterior dialysate 
solution, the dialysis method was tested. Figure 29 depicts the macroscopic appearance 
of the dialysis procedure during the experiment. By visual inspection, it can be seen the 
formation of a precipitate within the dialysis membrane. Further, the dilution of this 
precipitate in a 100 mM phosphate buffer + NaCl 0.3 M pH 7, was also attempted, 
although with no success. The proteins denaturation/precipitation has made impossible 
the resuspension in a buffer aqueous solution.  
 
 
Figure 29 – Dialysis of a top phase sample, corresponding to an ABS composed of wt % 
[N4444][HEPES] + 22.9 wt %  C6H5K3O7 + 57.1 wt % WSPF, using a solution of phosphate 
buffer pH 7.0 (A) 60 min (B) 120 min. 
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Taking into account the difficulties regarding the pellet solubilization, additional 
experiments were carried out using solutions of SDS. SDS has a typical surfactant 
structure, having a polar group, i.e., a hydrophilic head, and a hydrocarbon hydrophobic 
chain. Because of its amphiphilic nature, SDS is able to solubilize hydrophobic 
compounds in solution. As reported, at low concentrations detergents bind weakly to the 
exposed hydrophobic regions of proteins preventing aggregation (168). These compounds 
can also successfully promote the refolding of unfolded proteins without aggregation 
(168,170). The aim of using a SDS solution in some of the traditional protein precipitation 
experiments stated above was to induce the proteins solubilization, aiming the pellet 
ressuspension and a further protein profile analysis.  
The macroscopic appearance of the dialysis procedure, using a 4 % (w:v) and 6 % 
(w:v) SDS solution within the dialysis membrane is displayed in Figure 30. As 
previously, it is noticeable the formation of a precipitate in the dialysis membrane. The 
attempt of diluting these precipitated protein in the 100 mM phosphate buffer + NaCl 0.3 
M, pH 7 was still not successfully accomplished.  
 
 
Figure 30 – Dialysis of a top phase sample, belonging to an ABS composed of 20.1 wt % 
[N4444][TES] + 28.2 wt % C6H5K3O7 + 51.7 wt % WSPF, in a solution of phosphate buffer pH 
7.0 (A) combined with a 4 (w/v) % SDS solution (60 min), (B) combined with a 6 (w/v) % SDS 
solution (120 min). 
 
The next procedure tested was the ultrafiltration method. The results obtained from 
these tests were also not satisfactory, since again the same problems on the pellet 
solubilization in the 100 mM phosphate buffer + NaCl 0.3 M, pH 7, were found. As 
before, the resuspension of the pellet in the adequate buffer, after the proteins 
(A)                                             (B) 
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precipitation was not successfully accomplished so that no SE-HPLC experiments could 
be conducted. The ultrafiltration procedure was also executed using two distinct SDS 
solutions. The solubilization of the pellet was accomplished with success when using a 
10 % (w:v) SDS solution. The results obtained are presented in Figure 31. Taking into 
account the results presented in the chromatogram, it is possible to notice the interference 
of the SDS with the protein profile analysis. As reported, to permit the HPLC analysis, 
the concentration of SDS in the sample must be reduced to below 0.01 % (171). However, 
the complete solubilization of the pellet was not achieved with this concentration and no 
additional studies were performed.     
 
Figure 31 – Chromatogram of the bottom phase ( ̶ ), top phase  ( ̶ ) and top phase after 
ultrafiltration using a 10 % (w:v) SDS solution  ( ̶ ) of a system composed of 20.0 wt % 
[P4444][Tricine] + 29.0 wt % C6H5K3O7 + 51 wt % WSPF. 
 
3.5 – Conclusions 
In this chapter we tested the ability of two different protein precipitation techniques, 
acetone and TCA precipitation, plus ultrafiltration and dialysis, to recover the IgY from 
the IL-rich phase aiming at analysing the proteins profile by HPLC. Acetone 
precipitation, ultracentrifugation and dialysis were tested; however, no successful results 
were obtained. The failure of these procedures was mainly due to difficulties regarding 
the pellet solubilization in an adequate phosphate buffer which prevented the further study 
on the proteins profiles by HPLC. Regarding the TCA precipitation technique, in spite of 
the facility concerning the pellet solubilization, it led to proteins losses and denaturation. 
Moreover, a surfactant (SDS) was also used with the aim of solubilizing the proteins pellet 
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and thus to allow the proteins profile study. Despite of the satisfactory results concerning 
the proteins solubilization, this compound revealed to major interfere with the protein 
profile analysis by HPLC, when used above at high concentrations (still required to 
dissolve the pellet).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4 - Final remarks  
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4.1 – Conclusions and future work 
The main purpose of this work consisted on the development of an alternative 
platform for the selective extraction and purification of the IgY, from egg yolk, using 
ABS composed of biocompatible and self-buffering ILs, the GB-ILs.  
The GB-ILs investigated, namely [P4444][CHES], [P4444][MES], [P4444][HEPES], 
[P4444][TES], [P4444][Tricine], [N4444][CHES], [N4444][MES], [N4444][HEPES], 
[N4444][TES] and [N4444][Tricine] were at first combined with C6H5K3O7, a biodegradable 
salt, for the ABS formation. Their phase diagrams were ascertained and then the 
extraction experiments, using the WSPF from egg yolk, were performed. However, with 
these systems the extraction and purification of the IgY was not successfully achieved. In 
all the studied systems, no proteins were detected at the salt-rich phase and all proteins 
belonging to the WSPF revealed to have preference for the IL-rich phase. The systems 
composed of [P4444][HEPES], [N4444][HEPES] and [N4444][TES] shown a significant 
visible turbidity, suggesting that some proteins present in the WSPF precipitated. The 
SDS-PAGE results of these systems did not reveal any band matching the IgY light chain 
(25 kDa). Only β–livetin band (38 kDa) was detected, and a band around 65 kDa, which 
can correspond to the IgY heavy chain and/or correspond to other contaminant proteins. 
Regarding the IgY quantification, which was carried out through the analysis of the 
intensity of the IgY light chain band, favourable results were obtained with the ABS 
composed of 20.1 wt % [N4444][CHES] + 16.9 wt % C6H5K3O7. This system was found 
to be also the most promising concerning the stability of the proteins of the WSPF of egg 
yolk at the GB-IL-rich phase. 
Finally, four techniques were applied with the aim of isolating the proteins present at 
the IL-rich phase so that their profile could be evaluated by SE-HPLC. Acetone and TCA 
precipitations, dialysis and ultrafiltration techniques were applied at this stage. In three 
of the experiments, acetone, dialysis and ultrafiltration, the precipitated proteins were not 
able to be resuspended in an aqueous buffer medium. SDS was further employed to 
facilitate the proteins dissolution. However, some major drawbacks were found, namely 
the failure in the proteins solubilisation and the need of higher concentrated SDS 
solutions, which interferes with the protein profile evaluation by HPLC. 
Based on the results gathered in this work, the next step is to implement a successful 
method that could allow the complete extraction and purification of IgY from egg yolk. 
Nevertheless, the ABS investigated in this work are not promising alternatives and other 
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phase-forming components should be evaluated in the future. Moreover, it will be of high 
importance to identify the two major WSPF contaminant proteins by techniques such as 
MS/MS. Additional investigations on the protein stability and activity, such as Circular 
dichroism, should also be carried out to better understand the effects of the phase-forming 
components through the IgY stability. Moreover, after the IgY complete purification, the 
recycling nature of the ABS should be used aiming at decreasing the cost involved. The 
systems used in this work could be an adequate strategy for future investigation due to 
their benign and biocompatible character and since they already proved to maintain the 
integrity of other proteins. However, they do not seem adequate candidates for purifying 
IgY and other ABS composed of GB-ILs with different cations and combined with 
polymers, and as previously investigated (139), should be studied in detail.
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Appendix A: Experimental binodal data 
for the system composed of K3PO4 + 
[C4mim]Cl + H2O 
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A.1. Phase diagrams of the ternary systems composed of K3PO4 + [C4mim]Cl + H2O 
 
Figure A. 1 – Phase diagram for the ternary system composed of K3PO4 + [C4mim]Cl + H2O at 
(25 ± 1) °C: this work (♦), literature data (■) (140).  
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Appendix B: HPLC calibration curve 
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B.1. HPLC Calibration curve for IgY 
 
Figure B. 1 – HPLC calibration curve for IgY (purified using the EggsPure IgY commercial 
kit). 
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Appendix C: SDS-PAGE calibration 
curve 
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C.1. – SDS-PAGE of a gel load with 10 µg of pure IgY, at different concentrations, 
stained with Coomassie blue 
 
Figure C. 1 – SDS PAGE gel – calibration curve. 
 
C.2 – SDS-PAGE calibration curve obtained through the analysis of the intensity of the 
IgY light chain bands, using the GenoSoft software, from VWR 
 
Figure C. 2 – SDS-PAGE calibration curve. 
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Appendix D: Experimental binodal data 
for the system composed of 
[N4444][CHES] + C6H5K3O7 + H2O 
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D.1. Phase diagrams of the ternary systems composed of [N4444][CHES] + C6H5K3O7 + 
H2O 
 
Figure D. 1 – Phase diagram for the ternary system composed of [N4444][CHES] + C6H5K3O7 + 
H2O this work (♦), literature data (■) (25). 
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Appendix E: Experimental binodal data 
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E.1. Experimental binodal data for systems composed of GB-IL + salt + H2O 
Table E. 1- Experimental weight fraction data for the binodal curve of the systems composed of 
of [P4444][GB] (1) + C6H5K3O7 (2) at (25 ± 1) °C. 
[P4444][CHES] [P4444][HEPES] 
Mw = 465.71 g.mol-1 Mw = 496.72 g.mol-1 
100 w1 100 w2 100 w1 100 w2 100 w1 100 w2 
45.8725 5.1594 52.4356 3.3809 19.9875 20.6444 
33.0703 7.9812 50.8571 3.7208 19.7789 20.7202 
31.4785 8.3151 48.7809 4.0110 19.1789 21.1907 
30.7663 8.8449 47.0015 4.6767 18.9802 21.2130 
29.4375 9.3324 45.9192 5.3926 18.5920 21.5111 
28.3701 9.5904 44.5339 5.6672 18.3375 21.7429 
27.4919 9.7877 43.2175 6.4013 17.9787 22.0167 
26.5363 10.3651 41.7748 7.2840 17.5852 22.2453 
25.3700 10.5256 40.9755 7.5740 17.0421 22.8133 
24.6482 10.8738 40.0870 8.0190 16.7673 22.9471 
23.8099 11.1523 38.5449 8.8895 16.3891 23.2295 
23.4740 11.3404 36.7448 9.5462 15.8899 23.6604 
22.5056 11.5514 35.8968 10.0308 15.5849 23.7256 
21.7753 11.7923 35.1236 10.5409 15.3261 23.9031 
20.9845 12.1692 34.3325 11.0165 15.0627 24.1947 
20.4830 12.3391 32.9362 11.8402     
19.7301 12.8603 31.8346 12.5471     
19.2710 12.8446 31.0433 12.8594     
19.0036 12.8981 30.2768 13.4966     
18.7101 13.0962 29.7060 13.8282     
18.1123 13.3936 29.2446 13.9475     
17.5929 13.5070 28.1301 14.9854     
17.2801 13.6192 27.2980 15.4338     
16.7026 13.8189 26.4976 15.8693     
16.0024 14.2690 26.2008 15.9438     
15.6821 14.4136 25.8698 16.2748     
43.4923 5.5777 25.2302 16.7156     
41.4743 5.9829 24.9559 16.7906     
37.6457 7.0174 23.9968 17.4865     
35.4748 7.5777 23.5426 17.7956     
    22.9207 18.2905     
    22.6492 18.3176     
    22.2784 18.5603     
    21.2308 19.6799     
    20.8939 19.9928     
    20.4733 20.1856     
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[P4444][MES] [P4444][TES] 
Mw = 453.66 g.mol-1 Mw = 487.67 g.mol-1 
100 w1 100 w2 100 w1 100 w2 100 w1 100 w2 100 w1 100 w2 
56.0860 3.7199 10.0759 26.2305 49.3274 11.0418 10.4352 33.0947 
49.2000 5.8793 9.8190 26.4062 46.6779 12.5385 10.0084 33.4136 
39.9060 9.0502 9.5313 26.6884 44.0800 13.7779 9.1108 34.1036 
35.6838 10.7092 9.2917 26.8819 41.9299 14.6122 8.7044 34.5777 
32.2299 12.4537 8.7880 27.1615 40.1138 15.3985 8.3336 34.7034 
30.4517 13.5385 8.5138 27.3950 37.3418 16.5271     
28.0286 14.6491 7.5849 28.3888 34.7350 17.8627     
26.5401 15.3376 7.2616 28.6334 32.6036 19.2519     
25.6381 15.9660 7.1183 28.7600 31.2374 19.9006     
20.3539 19.6793     28.1143 22.0356     
19.8426 20.0167     26.3828 22.8026     
19.1169 20.4386     25.1128 23.4566     
18.7675 20.6581     24.5141 23.8630     
18.2459 20.8573     23.6911 24.3018     
17.9733 20.9879     22.7221 25.0937     
17.4030 21.4728     22.0661 25.4115     
16.9966 21.6709     21.5211 25.6630     
16.8141 21.7022     20.9795 25.8474     
16.5786 21.8329     20.2755 26.2981     
16.3307 22.0440     19.6014 26.7392     
16.0450 22.1776     18.3204 27.4774     
15.5163 22.6462     17.7554 27.8490     
15.1383 22.8364     17.3485 28.0255     
14.7511 22.9795     16.8705 28.3363     
14.2062 23.4197     16.1936 28.8914     
13.0638 24.1036     15.7599 29.0546     
12.9685 24.1744     15.3022 29.3814     
12.8049 24.2182     14.8725 29.6818     
12.5917 24.4750     14.5128 29.9909     
12.4553 24.5281     14.1003 30.3482     
12.3524 24.5791     13.8150 30.4762     
12.0765 24.8012     13.1270 30.9739     
11.7216 25.1559     12.5738 31.3816     
10.9443 25.6166     11.9999 31.7973     
10.6865 25.7738     11.4861 32.2455     
10.3012 26.0616     10.8326 32.6925     
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[P4444][Tricine] 
Mw = 437.59 g.mol-1 
100 w1 100 w2 100 w1 100 w2 100 w1 100 w2 
42.1255 12.6009 20.2641 27.4060 12.0250 34.0183 
40.3602 13.4219 20.0440 27.4713 11.8725 34.1810 
38.4601 14.4712 19.6646 27.8548 11.7110 34.3599 
37.2505 15.2329 19.4356 28.0177 11.5823 34.4851 
35.3379 16.3926 19.2146 28.1671 11.4282 34.6641 
32.6121 18.6625 18.8964 28.4463 11.3124 34.7944 
31.5688 19.2229 18.6063 28.7423 11.1593 34.8316 
30.1933 20.2199 18.3036 29.0215 11.0294 35.0037 
28.0745 21.6510 18.1074 29.1358 10.8889 35.1658 
27.1834 22.1727 17.7775 29.4780 10.8121 35.1672 
26.4801 22.6583 17.5843 29.5748 10.7023 35.3094 
32.2737 18.5240 17.4062 29.7475 10.4568 35.5745 
31.5877 18.9671 17.1936 29.8764     
30.9769 19.3892 16.9327 30.1473     
30.4459 19.6828 16.6746 30.3763     
29.8602 20.0574 16.5059 30.5192     
29.3288 20.4102 16.2517 30.7703     
28.7964 20.7798 16.0879 30.8671     
27.9689 21.6115 15.8639 31.0559     
27.5021 21.9881 15.6137 31.2773     
27.0526 22.2898 15.3613 31.5346     
26.6139 22.5766 15.2180 31.5846     
26.1790 22.8039 14.9933 31.7975     
25.5152 23.4747 14.7745 31.9996     
25.1113 23.7524 14.5414 32.2434     
24.7146 23.9830 14.2661 32.4125     
24.2941 24.1475 14.0897 32.6000     
23.9505 24.3704 13.9659 32.6448     
23.4108 24.9376 13.7769 32.8457     
23.0802 25.1276 13.6422 32.9745     
22.7777 25.3079 13.4665 33.1494     
21.9759 25.9534 13.2741 33.2291     
21.6897 26.1745 13.0964 33.4211     
21.2422 26.6289 12.8799 33.7079     
20.9856 26.7786 12.7729 33.7572     
20.7143 26.9484 12.4852 33.9822     
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Table E. 2 - Experimental weight fraction data for the binodal curve of the systems composed of 
[N4444][GB] (1) + C6H5K3O7 (2) at (25 ± 1) °C. 
[N4444][CHES] [N4444][HEPES] [N4444][MES] 
Mw = 448.74 g.mol-1 Mw = 479.75 g.mol-1 Mw = 436.69 g.mol-1 
100 w1 100 w2 100 w1 100 w2 100 w1 100 w2 100 w1 100 w2 
57.5741 4.3595 6.0328 23.0630 34.9668 7.8678 42.2318 6.3505 
49.7951 5.4885     26.5656 14.0779 34.4280 10.1559 
45.0789 6.4316     20.5902 19.8164 25.2272 17.3299 
42.4844 7.3569     15.6250 26.0832 15.5028 23.0078 
40.4427 8.2403     9.5904 31.9512 6.7431 33.2543 
37.8860 8.7157     5.6848 38.1506 3.4741 38.0405 
35.7309 9.3461             
34.6828 9.9063             
32.7218 10.8505             
29.9862 11.6212             
25.5988 13.5087             
24.1441 13.9681             
23.1690 14.3891             
20.0463 14.9631             
19.2217 15.2093             
16.0534 16.6588             
14.9346 17.0590             
13.8988 17.6751             
13.3392 17.7773             
12.1397 18.4118             
11.2020 18.9461             
10.3645 19.5405             
10.0122 19.6938             
9.4483 19.8957             
9.1472 19.9609             
8.7535 20.7380             
8.4425 20.6750             
7.8725 21.1431             
7.6509 21.2652             
7.4447 21.5299             
7.2393 21.5823             
7.0532 21.6714             
6.9287 22.1551             
6.7150 22.5621             
6.4749 22.6996             
6.2308 22.8082             
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[P4444][TES] [P4444][Tricine] 
Mw = 470.70 g.mol-1 Mw = 420.62 g.mol-1 
100 w1 100 w2 100 w1 100 w2 100 w1 100 w2 
60.0979 7.1499 44.6489 10.7724 12.8619 32.5152 
38.1764 14.0610 43.3425 11.5793 12.2324 33.0209 
31.6561 17.2741 42.1253 12.2497 12.0106 33.1806 
21.8117 24.9401 41.0591 12.7489 11.6513 33.4869 
17.4213 29.3787 39.8372 13.5505 11.4962 33.6289 
10.4669 35.3515 38.1933 14.6085 11.1564 33.8981 
4.4736 41.3063 36.2742 15.7678 10.4995 34.4976 
32.6036 19.2519 34.6087 16.7694 9.9389 35.0097 
    33.1372 17.7943 9.4991 35.3803 
    32.1573 18.1785 9.1337 35.7540 
    31.7469 18.3389 8.6148 36.2365 
    31.0114 18.8360 8.0910 36.6959 
    29.9834 19.6339 7.7570 36.9904 
    28.1113 20.9998 7.3539 37.3906 
    26.4768 22.2000 7.1370 37.6344 
    25.9227 22.5364 6.7822 37.9600 
    25.2101 23.0306 6.4953 38.2110 
    24.4242 23.6589     
    23.4762 24.3404     
    22.9368 24.7026     
    22.3403 25.1777     
    21.8922 25.4478     
    21.3077 25.9037     
    20.7949 26.2962     
    19.8940 26.9181     
    18.9674 27.6444     
    18.5053 28.0635     
    18.3376 28.1522     
    17.7885 28.5883     
    17.0513 29.1451     
    16.3110 29.7432     
    15.7645 30.1447     
    15.2459 30.5384     
    14.6169 31.0718     
    14.1015 31.4787     
    13.5202 31.9596     
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Appendix F: Phase diagrams and TLs  
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F.1 – Phase diagrams and TLs for the ternary systems composed of GB-ILs + C6H5K3O7 
+ water 
 
Figure F. 1 - Phase diagrams and TLs for the ternary systems composed of [P4444][GB] + 
C6H5K3O7 + water, at (25 ± 1) °C and atmospheric pressure: binodal data (●), TL1 data (●), TL2 
data (●), adjusted binodal data using Equation 1 (-). 
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Figure F. 2 - Phase diagrams and TLs for the ternary systems composed of [P4444][GB] + 
C6H5K3O7 + water, at (25 ± 1) °C and atmospheric pressure: binodal data (●), TL1 data (●), TL2 
data (●), adjusted binodal data using Equation 1 (-). 
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Appendix G: HPLC chromatograms 
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G.1. HPLC chromatograms from the systems composed of [P4444][GB] + C6H5K3O7 + 
WSPF 
 
Table G. 1 – HPLC chromatograms from the WSPF ( ̶ ), top phase ( ̶ ) and bottom phase ( ̶ ) of 
the systems composed of [P4444][GB] + C6H5K3O7 + WSPF. 
ABS 
Chromatograms 
[GB-IL] 
[IL]   
(wt %) 
[C6H5K3O7] 
(wt %) 
[WSPF] 
(wt %) 
[P4444][CHES] 20 13.5 66.5 
 
[P4444][HEPES] 20 22 48 
 
[P4444][MES] 20 21 49 
 
[P4444][TES] 20 28 52 
 
[P4444][Tricine] 20 29 51 
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G.2. HPLC chromatograms from the systems composed of [N4444][GB] + C6H5K3O7 + 
WSPF 
 
Table G. 2 - HPLC chromatograms from the WSPF ( ̶ ), top phase ( ̶ ) and bottom phase ( ̶ ) of 
the systems composed of [N4444][GB] + C6H5K3O7 + WSPF. 
ABS 
Chromatograms 
[GB-IL] 
[IL] 
(wt %) 
[C6H5K3O7] 
(wt %) 
[WSPF] 
(wt %) 
[N4444][CHES] 20 17 63 
 
[N4444][HEPES] 20 23 47 
 
[N4444][MES] 20 22 48 
 
[N4444][TES] 20 28.5 51.5 
 
[N4444][Tricine] 25 30 45 
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H.1. – FT-IR spectra of the ABS composed of [P4444][GB] + C6H5K3O7 + WSPF 
 
Figure H. 1 – FT-IR spectra from the top phase of the ABS composed of: ( ̶ ) [P4444][CHES], ( ̶ ) 
[P4444][HEPES], ( ̶ ) [P4444][MES], ( ̶ ) [P4444][TES] and ( ̶ ) [P4444][Tricine] and ( ̶ ) WSPF. 
 
H.12 – FT-IR spectra of the ABS composed of [N4444][GB] + C6H5K3O7 + WSPF 
 
Figure H. 2 - FT-IR spectra from the top phase of the ABS composed of: ( ̶ ) [N4444][CHES], ( ̶ ) 
[N4444][HEPES], ( ̶ ) [N4444][MES], ( ̶ ) [N4444][TES] and ( ̶ ) [N4444][Tricine] and ( ̶ ) WSP 
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Table H. 1 – Comparison of the second derivative peak values from the top phase of the systems composed of [P4444][GB]-IL and the WSPF, with the literature data. 
 Wave length (cm-1) 
 (158) (157) (162) WSPF [P4444][CHES] [P4444][HEPES] [P4444][MES] [P4444][TES] [P4444][Tricine] 
β–turn 1667±1.0 1655-1675 1660-1667 1660 1660 1656 1660 1660 1658 
1675±1.0 1680-1696 1676-1680 1667 1667 1667 1667 1667 1667 
1680±2.0     1673 1673 1673 1673 1673 1673 
1685±2.0      1682 1682 1682 1682 1682 1682 
      1688 1688 1687 1688 1687 1688 
      1694 1694 1694 1694 1694 1694 
          1697       
α–helix 1656±2.0 1650-1657 1650-1658 1656 1651 1651 1651 1651 1651 
          1656       
Random coil 1648±2.0 1640-1651 1640-1650 1642 1642 1642 1644 1641 1644 
      1649 1644     1643   
β-sheet 1624±1.0 1626-1640 1615-1620 1615 1615 1615 1615 1615   
1627±2.0 1612-1642 1628-1645 1623 1621 1623 1621 1621 1621 
1633±2.0 1670-1690 1686-1697 1629 1627 1626 1627 1627 1627 
1638±2.0       1633 1634 1628 1636 1634 1633 
1642±1.0     1637 1642 1633 1639 1641 1639 
1691±2.0      1642 1644 1638 1644 1643 1644 
1696±2.0     1673 1673 1642 1673 1673 1673 
      1682 1682 1673 1682 1682 1682 
      1688 1688 1682 1688 1687 1688 
      1694 1694 1687 1694 1694 1694 
          1694       
          1697       
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Table H. 2 – Comparison of the second derivative peak values from the top phase of the systems composed of [N4444][GB]-IL and the WSPF, with the literature data. 
 
 
Wave length (cm-1) 
 (158) (157) (162) WSPF [N4444][CHES] [N4444][HEPES] [N4444][MES] [N4444][TES] [N4444][Tricine] 
β–turn 1667±1.0 1655-1675 1660-1667 1660 1658 1656 1660 1658 1658 
1675±1.0 1680-1696 1676-1680 1667 1667 1667 1667 1667 1667 
1680±2.0     1673 1673 1673 1673 1673 1673 
1685±2.0      1682 1682 1682 1682 1682 1682 
      1688 1688 1687 1688 1688 1688 
      1694 1694 1694 1694 1694 1694 
          1697       
α–helix 1656±2.0 1650-1657 1650-1658 1656 1650 1651 1651 1651 1651 
        1658 1656   1658 1658 
Random coil 1648±2.0 1640-1651 1640-1650 1642 1641 1642 1642 1642 1645 
      1649 1643   1644 1644   
β-sheet 1624±1.0 1626-1640 1615-1620 1615 1650         
1627±2.0 1612-1642 1628-1645 1623 1615 1615 1615 1615   
1633±2.0 1670-1690 1686-1697 1629 1621 1623 1621 1621 1621 
1638±2.0       1633 1629 1626 1627 1627 1627 
1642±1.0     1637 1634 1628 1634 1635 1634 
1691±2.0      1642 1641 1633 1642 1642 1639 
1696±2.0     1673 1643 1638 1644 1644 1645 
      1682 1673 1642 1673 1673 1673 
      1688 1682 1673 1682 1682 1682 
      1694 1688 1682 1688 1688 1688 
        1694 1687 1694 1694 1694 
        1697 1694       
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